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ABSTRACT OF DISSERTATION

ADRENOCORTICOSTEROID RECEPTOR EFFECTS
ON HIPPOCAMPAL NEURON VIABILITY
Glucocorticoid activation of two types of adrenocorticosteroid receptors (ACRs), the
mineralocorticoid receptor (MR) and the glucocorticoid receptor (GR), influences hippocampal
neuron vulnerability to injury.

Excessive activation of GR may compromise hippocampal

neuron survival after several types of challenge including ischemic, metabolic, and excitotoxic
insults. In contrast, MR prevents adrenalectomy-induced loss of granule neurons in the dentate
gyrus. The present thesis addresses the respective roles of MR and GR in modulating neuronal
survival following two forms of neuronal injury, excitotoxicity and traumatic brain injury. Male
Sprague-Dawley rats were pretreated with MR antagonist spironolactone or GR antagonist
mifepristone (RU486) and subsequently injected with kainic acid, an excitotoxic glutamate
analog, or injured with a controlled cortical impact.

Twenty-four hours following injury,

hippocampal neuron survival was measured to test the hypotheses that MR blockade would
endanger and GR blockade would protect hippocampal neurons following injury. Messenger
RNA levels of viability-related genes including bcl-2, bax, p53, BDNF, and NT-3 were also
measured

to

test

the

hypothesis

that

ACR

regulation

of

these

genes

would

correlate with neuronal survival. In addition, ACR mRNA levels were measured following
receptor blockade and injury to test the hypothesis that glucocorticoid signaling is altered
following neuronal injury via regulation of ACR expression.
Mineralocorticoid receptor blockade with spironolactone increased neuronal vulnerability to
excitotoxic insult in hippocampal field CA3, and GR blockade with RU486 prevented neuronal
loss after traumatic brain injury in field CA1. These results are consistent with the hypotheses
that MR protects and GR endangers hippocampal neurons.

Adrenocorticosteroid receptor

blockade decreased mRNA levels of the anti-apoptotic gene bcl-2 in select regions of uninjured
hippocampus, yet ACR regulation of bcl-2 did not consistently correspond with measures of
neuronal survival after injury. Kainic acid decreased MR mRNA levels in CA1 and CA3, while
both kainic acid and controlled cortical impact dramatically decreased GR mRNA levels in
dentate gyrus. These data suggest that injury modulation of glucocorticoid signaling through
regulation of ACR expression may influence hippocampal neuron viability following injury.

KEYWORDS: Mineralocorticoid Receptor, Glucocorticoid Receptor, Messenger RNA, Kainic
Acid, Traumatic Brain Injury
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Chapter One: Introduction
Adrenocorticosteroid receptors in brain
Glucocorticoids are steroid hormones that play an essential role in adaptation to stress.
Named for their profound effects on glucose metabolism, glucocorticoids stimulate
gluconeogenesis, mobilize stored energy, and inhibit subsequent energy storage during the stress
response. In addition to regulating metabolism, glucocorticoids also increase cardiovascular
tone, inhibit growth and reproductive capabilities, restrain immune and inflammatory responses,
and influence learning and memory (Munck et al., 1984; Sapolsky et al., 2000). Glucocorticoids
are essential for surviving stress, but excessive exposure can have detrimental effects such as
hypertension, steroid diabetes, immunosuppression, inhibition of growth, and infertility (Munck
et al., 1984; Sapolsky et al., 1986; McEwen and Stellar, 1993). Elevated levels of the steroid
may also contribute to the development of affective disorders such as depression (De Kloet et al.,
1998) and neuropathological processes including Alzheimer’s disease (Landfield et al., 1992)
and age-related neurodegeneration (Sapolsky et al., 1986; Landfield and Eldridge, 1991;
McEwen, 1992). Furthermore, many studies have demonstrated that excessive exposure to
glucocorticoids increases neuronal vulnerability to many types of challenge including ischemia,
excitotoxicity, and oxidative stress (see Sapolsky, 1994).
At the cellular level, glucocorticoid effects are mediated by two types of ligand-activated
receptors, the mineralocorticoid receptor (MR) and the glucocorticoid receptor (GR). These
adrenocorticosteroid receptors (ACRs) are differentially activated in different glucocorticoid
contexts; MR is extensively activated at basal hormone levels, while GR is activated by high
glucocorticoid concentrations such as those experienced during stress or circadian peak (Reul
and de Kloet, 1985; Reul et al., 1987). This arrangement suggests that the MR mediates tonic
influences of glucocorticoids, while GR drives glucocorticoid actions aimed at restoring
homeostasis (De Kloet and Reul, 1987). The dichotomous activation of the receptors also
implies that MR maintains normal neuronal function while GR mediates the deleterious effects
of excessive glucocorticoids. Studies demonstrating rescue of dentate gyrus granule neurons
from adrenalectomy-induced death provide some support for the notion that MR has
neurotrophic properties (Woolley et al., 1991). In addition, numerous studies have demonstrated
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that chronic GR activation compromises neuronal survival in hippocampus (see Sapolsky, 1994),
a structure particularly rich in ACR expression (Reul and de Kloet, 1985) and particularly
vulnerable to neuronal injury and degeneration (see Sapolsky, 1994).
Improved understanding of the mechanisms underlying pathogenic effects of glucocorticoids
is of crucial importance to facilitate treatment of neurodegenerative and psychiatric illness. The
negative effects of chronic exposure to supraphysiological glucocorticoid levels have been well
established in animal models (Sapolsky, 1985; Sapolsky and Pulsinelli, 1985; Sapolsky, 1986a,
b; Elliott et al., 1993; Stein-Behrens et al., 1994a), and in vitro studies provide convincing
evidence that deleterious glucocorticoid effects are mediated by GR (Packan and Sapolsky,
1990; Behl et al., 1997b). Some studies demonstrate that GR blockade with antagonist drug
mifepristone (RU486) can protect cultured cells against glucocorticoid toxicity (Packan and
Sapolsky, 1990; Behl et al., 1997b; Behl et al., 1997a). However, the potential for attenuating
physiological glucocorticoid neurotoxicity with GR blockade has not been thoroughly examined
in vivo. One previous study has demonstrated transient RU486 protection against ischemiainduced hippocampal cell loss (Antonawich et al., 1999), but RU486 protection against other
forms of neuronal injury has not been studied in animal models. Furthermore, the possible
neuroprotective role of normal MR activation has not been previously addressed.
The current thesis aims to evaluate the respective roles of MR and GR on hippocampal
neuron survival in vivo under conditions of neuronal challenge. Adrenocorticosteroid receptor
regulation of neuronal viability was assessed after administration of ACR antagonist drugs and
injury with kainic acid, an excitotoxic glutamate analog, or controlled cortical impact, a model of
experimental traumatic brain injury. Following antagonist pretreatments and injury, survival of
challenged neurons, neuronal expression of viability-related genes, and neuronal expression of
ACR mRNAs were measured to test the hypotheses that (1) MR blockade would decrease
hippocampal neuron survival of injury and expression of genes associated with neuronal
viability, (2) GR blockade would increase hippocampal neuron survival of injury and expression
of genes associated with neuronal viability, and (3) glucocorticoid signaling is altered through
regulation of ACR expression following injury.
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The hypothalamic-pituitary-adrenal axis
Glucocorticoid secretion is regulated by the hypothalamic-pituitary-adrenal (HPA) axis
(Figure 1.1). Perception of stress or circadian drive stimulates the paraventricular nucleus of the
hypothalamus to release corticotropin-releasing hormone (CRH) and other adrenocorticotropinreleasing hormone (ACTH) secretogogues into the hypophysial portal system in the median
eminence. The neuropeptides stimulate anterior pituitary release of ACTH, which travels though
systemic circulation and promotes synthesis and release of glucocorticoids from the adrenal
cortex [see (Antoni, 1986; Jones and Gillham, 1988)]. Circulating glucocorticoids subsequently
inhibit their own release by acting at multiple levels of the HPA system including brain and
pituitary (Keller-Wood and Dallman, 1984; Jones and Gillham, 1988). This negative feedback
system participates in termination of the stress response and prevents overexposure to catabolic
glucocorticoid effects that might threaten homeostasis (Munck et al., 1984). Hypothalamicpituitary-adrenal dysregulation and elevated basal cortisol levels have been associated with
affective disease and cognitive decline in humans (Sapolsky et al., 1986; Martignoni et al., 1992;
Axelson et al., 1993).
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Figure 1.1. The hypothalamic-pituitary-adrenal axis. Stress or circadian drive stimulate the
paraventricular nucleus of the hypothalamus (PVN) to release corticotropin releasing hormone
(CRH), which stimulates release of adrenocorticotropin-releasing hormone (ACTH) from the
anterior pituitary.

ACTH promotes glucocorticoid release from the adrenal cortex.

Glucocorticoids act at multiple levels to inhibit further HPA activation.
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Properties of adrenocorticosteroid receptors
As members of the nuclear hormone receptor superfamily, MR and GR share a characteristic
three-domain structure consisting of an N-terminal transactivation domain, a central DNAbinding domain, and a carboxy-terminal ligand-binding domain (Evans, 1988) (Figure 1.2). The
non-conserved N-terminal domain provides unique transactivation properties to each receptor
(Evans, 1988). The highly conserved DNA-binding domain suggests that both receptor types
bind to identical response elements on target genes (Arriza et al., 1987).

In addition to

interaction with hormone ligand, the carboxy-terminal domain also mediates binding to
chaperone proteins, nuclear translocation, dimerization, and transactivation (Bertorelli et al.,
1998). Rat and human ACR sequences are highly homologous; comparisons indicate complete
identity in MR and GR DNA-binding domains and high coincidence in steroid-binding domains
(Hollenberg et al., 1985; Miesfeld et al., 1986; Patel et al., 1989).

Figure 1.2. Functional domains of the rat glucocorticoid receptor (GR) and mineralocorticoid
receptor (MR).

Each protein consists of three main functional domains: an N-terminal

transactivation domain, a central DNA binding domain, and a carboxy-terminal hormone-binding
domain (Miesfeld et al., 1986; Picard and Yamamoto, 1987; Evans, 1988; Patel et al., 1989).
Approximate percentages of amino acid identity within each domain are based on human MR
and GR homology (Evans, 1988).
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Differences in ligand binding affinity underlie the differential activation of MR and GR with
increasing plasma glucocorticoid levels. The MR, also termed the “type I” receptor, binds
corticosterone with high affinity (Kd ∼ 0.5-1 nM), resulting in extensive occupation even at low
circulating glucocorticoid levels (Reul and de Kloet, 1985). The GR, or “type II” receptor, has a
lower affinity for corticosterone (Kd ∼ 2.5-5 nM) and is activated (in addition to MR) only at
high CORT levels as seen at the circadian peak or during stress (Reul and de Kloet, 1985). In
contrast to a simple dose-response relationship, this two-receptor system is capable of generating
unique cellular responses based on the strength of glucocorticoid signal.
Central nervous system distribution of adrenocorticosteroid receptors
The GR is widely expressed in the brain, in both neurons and glial cells (Fuxe et al., 1985;
van Eekelen et al., 1987; Ahima and Harlan, 1990). Particularly high levels of GR expression
are found in the hippocampal formation; other regions expressing moderate to high levels of GR
include the paraventricular nucleus of the hypothalamus, the lateral septum, brainstem
monoaminergic neurons, thalamic nuclei, the central amygdala, striatum, and layers of cortex
(Aronsson et al., 1988; Van Eekelen et al., 1988; Chao et al., 1989). Expression of MR is limited
mainly to limbic areas, with highest expression in the hippocampal formation (Reul and de
Kloet, 1985; Ahima and Harlan, 1990). Colocalization of both MR and GR has been reported in
dorsal subiculum, septum, amygdala, and particularly in hippocampus (Reul and de Kloet, 1985;
Van Eekelen et al., 1988). The distribution of ACRs varies by subregion in hippocampus
(Herman et al., 1989a; Herman, 1993) (Figure 1.3).

The rich expression of ACRs in

hippocampal neurons may contribute to their unusual vulnerability to challenge and their
extreme sensitivity to the neurotoxic effects of glucocorticoids.
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Figure 1.3. Microdistribution of mineralocorticoid receptor (MR) (panel A) and glucocorticoid
receptor (GR) (panel B) mRNAs in rat hippocampus. MR and GR mRNAs are heterogeneously
distributed within the hippocampal formation (Herman et al., 1989a; Herman, 1993). MR
mRNA levels are highest in CA2 and comparable in CA1, CA3, and dentate gyrus (DG) (panel
A). GR signal is highly expressed in CA1 and DG and low in CA3 (panel B).
Regulation of adrenocorticosteroid receptor expression
Adrenocorticosteroid receptor expression is subject to short-term and long-term regulation by
many factors, including glucocorticoids. Autoregulation of hippocampal ACR expression has
been demonstrated in adrenalectomized animals and in subjects treated with ACR antagonists
(i.e. receptor expression is increased in the absence of receptor activation). Results from several
studies are consistent with regulation of MR expression by MR (Chao et al., 1998a; McCullers
and Herman, 2001) and with regulation of GR expression by both MR (O'Donnell and Meaney,
1994; Chao et al., 1998a; McCullers and Herman, 2001) and GR (Herman et al., 1989a; Reul et
al., 1989; Chao et al., 1998a; Herman and Spencer, 1998; McCullers and Herman, 2001)
(Chapter Three).

Furthermore, ACR expression is subject to regulation by glucocorticoid

secretion during acute stress (Herman and Watson, 1995; Paskitti et al., 2000), chronic stress
(Sapolsky et al., 1984; Gomez et al., 1996; Paskitti et al., 2000), social conflict (Johren et al.,
1994), and the circadian rising phase (Herman et al., 1993). It is important to note that ACR
expression is differentially regulated by brain region, particularly across subfields of the
hippocampus (Herman, 1993).
Adrenocorticosteroid receptor expression is also regulated by numerous factors other than
glucocorticoids, emphasizing the importance of ACR regulation as a means for modulating
glucocorticoid signaling. Neurotransmitters appear to play a prominent role in regulating ACR
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levels; there is evidence for serotonergic (Seckl et al., 1990; Mitchell et al., 1992), noradrenergic
(Yau and Seckl, 1992), and dopaminergic (Antakly et al., 1987) regulation of neuronal ACR
mRNAs and/or receptor binding. Antidepressant drugs also affect ACR density, but whether
antidepressants act directly to alter ACR expression or indirectly by increasing monoamine
levels is unclear (Seckl and Fink, 1992). Disruption of hippocampal circuitry also influences
ACR mRNA expression; lesions of the medial septum (Yau and Seckl, 1992), dentate gyrus
(Brady et al., 1992), entorhinal cortex (O'Donnell et al., 1993), and central 5-HT lesions (Yau et
al., 1994) can regulate hippocampal ACR mRNA levels. Excitatory amino acids (Lowy, 1992)
and growth factors (Sarrieau et al., 1996) are among numerous other factors shown to regulate
ACR expression.
Expression of ACR mRNAs is regulated at multiple levels including transcription,
polyadenylation, and/or alternative splicing (see De Kloet et al., 1998). Splicing at the 3’-end of
human GR heteronuclear RNA results in at least two GR mRNA variants, GRα and GRβ
(Hollenberg et al., 1985). Notably, GRβ is not expressed in rat (Otto et al., 1997). Rat GR and
MR mRNAs exhibit heterogeneity in 5’-untranslated exon 1 (McCormick et al., 2000) (Kwak et
al., 1993; Zennaro et al., 1995). Interestingly, expression of rat GR mRNA variants can be
regulated by environmental manipulations (i.e. postnatal handling) (McCormick et al., 2000),
and select MR transcripts are regulated by glucocorticoids (Kwak et al., 1993). Splice variants
may exhibit different stabilities and/or translation efficiencies, influencing overall levels of ACR
expression based on the differential expression of transcripts (Kwak et al., 1993; Zennaro et al.,
1995).
Adrenocorticosteroid receptor activation
Adrenocorticosteroid receptors are activated upon the binding of glucocorticoid ligand,
specifically cortisol in human or corticosterone (CORT) in the rat. Unliganded ACRs reside in
the cytoplasm as part of a multi-protein complex containing two molecules of heat shock protein
(HSP) 90, a molecule each of hsp70, hsp56, p23, and an immunophilin (Pratt, 1993; Bruner et
al., 1997; Bertorelli et al., 1998). The chaperone complex facilitates hormone binding to the
receptor and participates in receptor trafficking (Pratt, 1993). Glucocorticoid binding induces a
conformational change in the ACR molecule that favors dissociation from the chaperone
complex (Pratt, 1993).

Following dissociation, the liganded receptors become
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hyperphosphorylated (Orti et al., 1992) and translocate into the nucleus (Picard and Yamamoto,
1987) where they act as transcription factors (Yamamoto, 1985).
Adrenocorticosteroid receptor regulation of gene transcription
Models proposed to explain ACR regulation of gene transcription identify chromatin
remodeling and stabilization of the transcriptional preinitiation complex as essential mechanisms
(Jenster et al., 1997).

Adrenocorticosteroid receptor regulation of these processes is

accomplished via binding to DNA response elements or through interactions with other
transcription factors (Figure 1.4). In the case of the former, the activated receptors can bind as
homo- or heterodimers (Luisi et al., 1991; Trapp et al., 1994) to specific DNA sequences called
glucocorticoid response elements (GREs). These palindromic sequences are located in or near
promoter regions of glucocorticoid-responsive genes and serve as inducible enhancer elements
(see Yamamoto, 1985). Response element-bound ACRs recruit coactivator proteins capable of
remodeling chromatin structure via histone acetyltransferase activity. By acetylating histone Ntermini, coactivators loosen nucleosomal structure and increase accessibility for other
transcription factors. The steroid receptors and coactivators may also stabilize assembly of the
preinitiation complex, thereby increasing the rate of transcription initiation (Jenster et al., 1997).
The MR and GR can repress gene transcription by recruiting corepressor proteins or by acting at
negative GREs, which differ in sequence from positive GREs (Drouin et al., 1993). It is
important to note that interactions with coactivator proteins will vary depending on dimer
configuration, with distinct transactivation properties conferred by each type of homo- or
heterodimer (Trapp et al., 1994).
Ligand-activated ACRs may also influence transcription of genes via interactions with other
transcription factors (Karin, 1998) (Figure 1.4).

For instance, GR modulates activity of

transcription factors including activator protein-1 (AP-1), cyclic AMP response element binding
protein (CREB), and nuclear factor-κB (NF-κB), in the absence of DNA binding (Herrlich,
2001). Steroid receptor cross-talk with transcription factors most frequently results in negative
interference, but synergism is also possible under specific conditions (i.e. when AP-1 is a
homodimer of c-Jun) (Diamond et al., 1990).

The exact molecular mechanism of steroid

receptor cross-talk has yet to be elucidated. Models for direct protein-protein interactions
between GR and other transcription factors have been proposed (McEwan et al., 1997).
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Adrenocorticosteroid receptors may also repress gene transcription by inducing specific
inhibitors of other transcription factors. For example, GR may repress NF-κB activity by
inducing IκB, an inhibitor of NF-κB (Auphan et al., 1995; Scheinman et al., 1995). The
evidence indicates that multiple mechanisms are likely to account for glucocorticoid-mediated
gene repression (see De Bosscher et al., 2000).
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Figure 1.4. Models for transcriptional regulation by adrenocorticosteriod receptors. Activated
mineralocorticoid receptors (MRs) or glucocorticoid receptors (GRs) bind DNA hormone
response elements as dimers or interact with other transcription factors to influence transcription
(McEwan et al., 1997; Karin, 1998; De Bosscher et al., 2000).

Possible mechanisms for

modulating transcription include: recruitment of transcription coactivators or repressors (A, B);
binding to negative hormone response elements (nGREs)(C); interference with activity of other
transcription factors (D); competive DNA binding (E, F); and induction of inhibitors of other
transcription factors (G).
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Adrenocorticosteriod receptor roles in neuronal viability
Differential ACR activation at varying glucocorticoid levels can elicit unique cellular
responses due to the distinct regulatory effects of MR and GR. Collaborative binding of MR/GR
heterodimers to GREs demonstrates the potential for ACR cooperation in regulating gene
expression (Trapp et al., 1994). In some cases, however, MR and GR effects appear to be quite
opposite. For instance, predominant MR activation at low glucocorticoid concentrations results
in very small depolarization-induced calcium (Ca2+) currents in CA1 pyramidal neurons (Karst et
al., 1994), while the additional occupation of GR at high glucocorticoid levels results in
relatively large Ca2+ currents (Kerr et al., 1992). Further, MR activation by low glucocorticoid
levels or aldosterone decreases accommodation and afterhyperpolarization amplitude in CA1,
enhancing excitatory transmission (Joels and de Kloet, 1990); in contrast, high glucocorticoid
levels

and

GR

agonist

RU28362

increase

accommodation

and

the

duration

of

afterhyperpolarization, suppressing CA1 excitability (Kerr et al., 1989). Differential activation
of GR can also elicit structural effects on hippocampal neurons that do not occur at lower, MRactivating levels. For instance, chronic exposure to GR-saturating glucocorticoid levels achieved
by 21-day corticosterone (CORT) administration (Woolley et al., 1990; Magarinos and McEwen,
1995) or repeated stress (Magarinos and McEwen, 1995) reversibly decreases both numbers and
length of apical dendritic branches in CA3 pyramidal neurons.
The preferential activation of MR or GR can also influence the survival of hippocampal
neurons. The vast majority of literature to date examines negative GR effects on hippocampal
neuron viability, as GR activation is associated with the exacerbation of several forms of
neuronal insult (Sapolsky, 1985; Sapolsky and Pulsinelli, 1985; Sapolsky, 1986a, b; Sapolsky et
al., 1988; Packan and Sapolsky, 1990; Elliott et al., 1993; Stein-Behrens et al., 1994a; Goodman
et al., 1996; McIntosh and Sapolsky, 1996a; Behl et al., 1997b). In contrast, MR activation is not
associated with reduced neuronal survival (Packan and Sapolsky, 1990), and there is some
evidence to indicate that MR may have trophic or neuroprotective effects (Woolley et al., 1991).
Excessive glucocorticoid receptor activation compromises hippocampal neuron viability
Chronic exposure to high concentrations of glucocorticoids can be toxic to neurons, with
preferential damage to the hippocampus (see Sapolsky, 1994). Studies describing hippocampal
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degeneration in aging male rats with elevated basal glucocorticoid levels provided the first
evidence of a physiological role for glucocorticoid neurotoxicity. Landfield and colleagues
demonstrated a correlation between the degree of glucocorticoid hypersecretion and the amount
of hippocampal degeneration in mid-aged rats (Landfield et al., 1978).

Removal of

glucocorticoids via adrenalectomy was subsequently shown to prevent the hippocampal cell loss
and glial reactivity (Landfield et al., 1981).

These studies led to the formation of the

“glucocorticoid hypothesis of brain aging and neurodegeneration”, which proposes that
glucocorticoids contribute to age-related degeneration of the hippocampus (Landfield and
Eldridge, 1991). Sapolsky and colleagues later demonstrated that chronic exposure to high
levels of glucocorticoids, achieved by repeated injection of corticosterone, resulted in the death
of hippocampal pyramidal neurons in rat (Sapolsky et al., 1985). It remains unclear whether
glucocorticoids alone are sufficient to induce neuronal death in hippocampus.
While glucocorticoids may not kill neurons directly, there is ample support for the notion that
chronic exposure to high levels of glucocorticoids increases the vulnerability of hippocampal
neurons to subsequent challenge (Sapolsky, 1985). In rat, administration of high physiologic
concentrations of CORT potentiates ischemic injury to CA3 neurons produced by the four-vessel
occlusion method of forebrain ischemia (Sapolsky and Pulsinelli, 1985). High CORT levels also
enhance damage induced in CA3 by the excitotoxin kainic acid (Sapolsky, 1985, 1986a, b;
Elliott et al., 1993; Stein-Behrens et al., 1994a) and in DG by the antimetabolite toxin 3acetylpyridine (Sapolsky, 1985, 1986b). Glucocorticoid exacerbation of excitotoxic (Sapolsky et
al., 1988; Packan and Sapolsky, 1990; Goodman et al., 1996) and metabolic (Sapolsky et al.,
1988) challenge is also seen in primary hippocampal cultures. Furthermore, in vitro experiments
have shown that glucocorticoids increase the amount of hippocampal cell death induced by
oxidative stress (Sapolsky et al., 1988; Goodman et al., 1996; McIntosh and Sapolsky, 1996a;
Behl et al., 1997b) and amyloid β-peptide toxicity (Goodman et al., 1996).
Despite the graded activation of GR with increasing CORT levels, it remains difficult to
differentiate between specific MR and GR effects at high CORT concentrations, as both receptor
types are activated. Likewise, both MR and GR are inactivated in adrenalectomized animals due
to the removal of endogenous CORT. In order to dissect the individual effects of each receptor
type, selective MR/GR agonists may be administered in adrenalectomized animals or in culture
to study the selective activation of a receptor type. Conversely, MR/GR antagonists may be
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administered to intact animals or in culture to observe the effects of loss of function of a specific
ACR type. A number of studies using ACR agonists and antagonists in vitro have provided
convincing evidence for the hypothesis that the endangering effects of excessive glucocorticoid
exposure are mediated by the GR. In primary hippocampal cultures, a specific GR agonist,
dexamethasone, exacerbates kainic acid damage, where the MR agonist aldosterone has no effect
(Packan and Sapolsky, 1990). In the same culture system, GR antagonist RU486 protects against
glucocorticoid/kainic acid synergy, but MR antagonist RU28318 does not prevent the damaging
glucocorticoid effects (Packan and Sapolsky, 1990).

Other in vitro studies provide strong

support for GR enhancement of amyloid β protein, hydrogen peroxide, and glutamate toxicity, as
dexamethasone exacerbates (Behl et al., 1997b) and RU486 prevents (Behl et al., 1997b; Behl et
al., 1997a) negative glucocorticoid effects with these types of insult. In vivo, RU486 transiently
protects gerbil CA1 neurons from ischemia-induced cell loss, indicating that blockade of GR can
prevent the detrimental effects of post-ischemia CORT elevations (Antonawich et al., 1999).
Mechanisms for glucocorticoid receptor endangerment of hippocampal neurons
Glucocorticoids can increase neuronal susceptibility to injury by inducing a state of
metabolic vulnerability (Sapolsky, 1985). In the absence of additional challenge, temporary
energy crisis induced by glucocorticoids is not likely to threaten neuronal survival. However, by
compromising cellular energy supplies, glucocorticoids can greatly intensify the toxicity of a
wide variety of insults that impair generation of energy (i.e. ischemia) or place pathogenic
demands on the neuron for energy (i.e. excitotoxicity) (Sapolsky, 1990). Glucocorticoids impair
glucose metabolism in regions including hippocampus, locus coeruleus, hypothalamic
paraventricular nucleus, median eminence, and pituitary anterior lobe (Kadekaro et al., 1988).
Activation of GR may compromise neuronal energy stores by impairing glucose transport, as
demonstrated in cultured hippocampal neurons and glia in vitro (Horner et al., 1990). Chronic
glucocorticoid exposure also markedly induces expression of ATP-requiring enzymes such as
glutamine synthetase and glycerol-phosphate dehydrogenase, which may result in the further
depletion of cellular ATP stores (Nichols and Finch, 1994). Energy supplementation with
glucose or mannose has been shown to attenuate glucocorticoid neurotoxicity in vivo (Sapolsky,
1986b) and in vitro (Sapolsky et al., 1988).
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Neuronal energy depletion following excessive glucocorticoid exposure has been proposed to
exacerbate hippocampal insult by contributing to excitotoxic cascades (Sapolsky, 1990). Under
normal conditions, glutamate interaction with postsynaptic receptors mobilizes free cytosolic
Ca2+ in the postsynaptic neuron in a highly regulated fashion. Glutamate is removed from the
synapse by energy-dependent glutamate transporters (Kanai et al., 1993).

Calcium in the

postsynaptic neuron is effectively buffered by Ca2+ binding proteins including calbindin and
parvalbumin, sequestered by cellular organelles such as smooth endoplasmic reticulum and
mitochondria, or extruded via ATP-dependent transporters including a Na+/Ca2+ exchanger and
the plasma membrane calcium pump (PMCA) (Blaustein, 1988). However, energy depletion and
necrotic insult can lead to the pathologic accumulation of synaptic excitatory amino acids,
leading to excessive influx of Ca2+ into the postsynaptic neuron. Energy crisis compromises
glutamate removal from the synapse and may even result in reversal of glutamate transporters
(Takahashi et al., 1997), resulting in the further depolarization-induced opening of voltage-gated
Ca2+ channels and NMDA-gated Ca2+ channels on the postsynaptic neuron. Energy deficits can
also lead to the failure of ATP-driven Ca+ sequestration and extrusion systems, exacerbating
increases in intracellular Ca2+ levels (see Tymianski and Tator, 1996). Excessive Ca2+ influx can
set in motion many destructive processes including mitochondrial failure, the degradation of
structural proteins by Ca2+-activated proteases (i.e. calpain)(Siman et al., 1989), and the
generation of free radicals [see (Choi, 1992; Tymianski and Tator, 1996)].
Many experimental studies support the theory that glucocorticoids contribute to excitotoxic
glutamate/Ca2+ cascades. Chronic exposure to high levels of glucocorticoids has been shown to
increase extracellular levels of excitory amino acids following kainic acid administration (SteinBehrens et al., 1992; Stein-Behrens et al., 1994b). Glucocorticoids also prolong intracellular
Ca2+ elevation after kainic acid treatment (Elliott and Sapolsky, 1992) and increase basal
intracellular Ca2+ levels (Elliott and Sapolsky, 1993) in culture. Furthermore, glucocorticoids
exacerbate Ca2+-mediated degenerative events in the hippocampus following intrahippocampal
kainic acid infusion, as measured by spectrin proteolysis and altered tau immunoreactivity
(Elliott et al., 1993; Stein-Behrens et al., 1994a).

Glucocorticoid exacerbation of 3-

acetylpyridine toxicity is eliminated with administration of an NMDA receptor antagonist,
aminophosphonovaleric acid, providing evidence that negative glucocorticoid effects are
dependent on activation of the NMDA receptor (Armanini et al., 1990).
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Glucocorticoids can also influence neuronal survival via genomic mechanisms.

High

glucocorticoid concentrations may modulate Ca2+ homeostasis by increasing P/Q- and L- type
Ca2+ channel subunit mRNA levels, as demonstrated in isolated CA1 neurons (Nair et al., 1998).
Glucocorticoids also decrease hippocampal mRNA levels of plasma membrane calcium pump
isoform 1 (PMCA1) (Bhargava et al., 2000), which regulates intracellular Ca2+ levels by
coupling ATP hydrolysis with Ca2+ extrusion. These changes in gene expression, if indicative of
changes in protein expression, are consistent with increased intracellular Ca2+ accumulation with
GR activation. Furthermore, glucocorticoid regulation of neurotrophin expression may lead to
decreased neurotrophic support and the exacerbation of neuronal insults. Immobilization stress
(Smith et al., 1995a) and CORT administration (Chao and McEwen, 1994; Smith et al., 1995a)
decrease hippocampal brain-derived neurotrophic factor (BDNF) mRNA levels and increase
hippocampal neurotrophin-3 (NT-3) levels in hippocampus.
Neurotrophic effects of mineralocorticoid receptor activation
The potentially damaging effects of GR activation at high glucocorticoid concentrations are
well documented.

In contrast, the MR, which is persistently activated even at basal

glucocorticoid levels (Reul and de Kloet, 1985), is not associated with neuronal energy depletion
or exacerbation of neuronal insult (Packan and Sapolsky, 1990). On the contrary, MR may
function in a neurotrophic manner, as activation of MR is required for the survival of dentate
gyrus granule neurons.

Removal of endogenous glucocorticoids by adrenalectomy causes

granule cell loss within as little as three days (Gould et al., 1990), and nearly all granule cells are
lost within three to four months after surgery (Sloviter et al., 1989). Administration of the
selective MR agonist aldosterone prevents adrenalectomy-induced granule neuron loss, but
treatment with GR agonist RU28362 provides only partial protection for DG granule neurons
(Woolley et al., 1991). Thus, MR occupation is necessary for maintenance of DG neuron
survival, but the role for GR is less clear (Woolley et al., 1991). MR activation also regulates
granule cell neurogenesis in DG, maintaining a balance between granule cell birth and cell death
(Gould et al., 1991). MR may regulate neurogenesis by enhancing excitatory input to the region
(Gould, 1994) or indirectly through regulation of neurotrophin expression (Lindholm et al.,
1994; Qiao et al., 1996).
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Kainic acid as a model of excitotoxicity
Kainic acid (KA) is a glutamate analog notable for its excitotoxic and epileptogenic effects.
Systemic or intracerebral injection of KA induces epileptiform seizures and cell loss in
hippocampus in a pattern similar to human temporal lobe epilepsy (Nadler et al., 1978; Ben-Ari
and Cossart, 2000). The extensive literature demonstrating glucocorticoid modulation of KA
excitotoxicity, the selective toxicity of KA in hippocampus, and the substantial but incomplete
neuronal loss following seizure indicate KA as an ideal model for use in studying ACR effects
on hippocampal neuron viability.
Glutamate receptors
Glutamate receptors are divided into two major categories - metabotropic and ionotropic
receptors.

Metabotropic glutamate receptors are coupled to G-protein-mediated second

messenger pathways; ionotropic glutamate receptors allow the direct influx of cations upon
activation. Ionotropic glutamate receptors are responsible for the majority of fast excitatory
synaptic transmission in the central nervous system.

Three types of ionotropic glutamate

receptors have been identified based on their preferential activation by each compound – the
AMPA, kainate, and NMDA receptors (Dingledine and McBain, 1999).
Non-NMDA glutamate receptor subunits are approximately 900 amino acid residues in
length, have a calculated molecular weight of approximately 100 kDa, and are predicted to have
four transmembrane domains (Keinanen et al., 1990). Non-NMDA receptors are formed by
homomeric or heteromeric associations of AMPA (GluR-1/-2/-3/-4) or kainate (GluR-5/-6/-7 and
KA-1/-2) receptor subunits.

Subunit composition may confer distinct functional and

pharmacological properties (Hollmann et al., 1991; Bettler and Mulle, 1995). Kainate receptors
exhibit significant structural homology to AMPA receptors and can be expressed in the same
cells as AMPA receptors, yet KA receptor subunits and AMPA receptor subunits do not seem to
coassemble (Frerking and Nicoll, 2000). Kainate receptors generate excitatory postsynaptic
potentials (EPSPs) in response to glutamate release (Frerking and Nicoll, 2000), and kainate
responses undergo rapid and total desensitization from which recovery is slow (Lerma et al.,
1997). As compared to AMPA receptor-mediated EPSPs, kainate-mediated EPSPs have smaller
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peak amplitude and slower decay kinetics. A controversial presynaptic role for kainate receptors
has also been proposed (see Malva et al., 1998).
NMDA receptors are believed to play a key role in glutamate neurotoxicity due to their high
Ca

2+

permeability as compared to non-NMDA ionotropic glutamate receptors (Rothman, 1987).

NMDA receptors are unique in that they require bound ligand and the voltage-dependent
removal of a Mg2+-dependent block to initiate activation, and the presence of glycine is required
for full activation (Malva et al., 1998). NMDA receptors are insensitive to AMPA and kainate
(Hollmann and Heinemann, 1994) but may be activated by kainate-induced seizures or
excitotoxic cascades (Ben-Ari and Gho, 1988).
Kainic acid excitotoxicity
The distribution of KA binding sites roughly corresponds to regional susceptibility to KA
excitotoxicity.

Regions displaying KA binding and sensitivity to KA toxicity include the

hippocampus, amygdala, entorhinal cortex, piriform cortex and insular cortex (Kohler and
Schwarcz, 1983). High-affinity kainate receptors are expressed at very high density in rat brain
in the mossy fiber synaptic region, or stratum lucidum of CA3 (Foster et al., 1981; Represa et al.,
1987). The epileptogenic effects of KA are attributed to excitation of CA3 neurons by postsynaptic kainate receptors at mossy fiber synapses (Ben-Ari and Gho, 1988). It is important to
note that degeneration of CA3 neurons is probably due to the sustained release of glutamate
subsequent to recurrent seizures, not to the activation of KA receptors per se (Coyle et al., 1981;
Ben-Ari, 1985; Ben-Ari and Cossart, 2000). Seizures generated in CA3 propagate to CA1 via a
network of recurrent collateral glutamatergic axons that interconnect pyramidal neurons.
Secondary activation of CA1, the major source of hippocampal output, leads to the spread of
seizures to other limbic structures including entorhinal cortex (Figure 1.5) (Ben-Ari and Cossart,
2000).
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Figure 1.5. Schematic diagram of the intrinsic circuitry of the hippocampal formation (adapted
from Amaral and Witter, 1989). The hippocampal formation is composed of four basic regions:
the entorhinal cortex (EC), the dentate gyrus (DG), the hippocampus proper (which may be
divided into subfields CA1, CA2, and CA3), and the subicular complex (S).

The major

connections linking hippocampal subfields are glutamatergic and largely unidirectional. Input
from EC reaches DG via the perforant path. Granule cells of the DG project to the CA3 field via
mossy fibers. CA3 pyramidal neurons give rise to Schaffer collaterals, which terminate on CA1
pyramidal neurons. CA1 pyramidal neurons project to S, which projects to regions including
EC.
The behavioral effects of systemic KA administration have been described in detail (Sperk et
al., 1983). Approximately five minutes after injection, most animals assume a catatonic posture
with staring behavior. Within approximately one hour, subjects develop generalized clonic-tonic
convulsions accompanied by frequent rearing, falling over to one side, “wet dog shakes”, and
hemorrhagic foam from the mouth. Convulsions often subside two hours after injection and are
replaced by a phase of motor hyperactivity. In more severely affected animals, the convulsive
phase may last up to 4-5 hours after KA injection. After twenty-four hours the animals appear
physically exhausted. Rare convulsions may still occur spontaneously or in response to noise or
handling (Sperk et al., 1983).
Kainic acid lesion preferentially destroys hippocampal pyramidal cells, particularly those of
region CA3 (Nadler et al., 1978). Neurons of CA1 are vulnerable to a lesser degree, and DG
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granule cells are relatively insensitive to KA excitotoxicity (Nadler et al., 1978; Kohler and
Schwarcz, 1983). As early as one to three hours after exposure, damaged neurons appear
shrunken, with darkly stained cytoplasm and pyknotic nuclei (Sperk et al., 1983) (Figure 1.6).
Some neurons appear swollen, containing small vacuoles in mitochondria and in cytoplasm due
to swelling of endoplasmic reticulum and Golgi apparatus (Sperk et al., 1983). Cell death
induced by KA administration has been classified as necrotic (Sperk et al., 1983; Fujikawa et al.,
2000) yet exhibits some characteristics consistent with apoptosis such as TUNEL positivity and
DNA laddering (Fujikawa et al., 2000). Damaged neurons appear to be partially removed by
three days after injection but may be seen for at least two weeks (Nadler et al., 1978). Neuronal
degeneration is accompanied by edema, perivenous hemorrhage, gliosis, and vacuolization of the
neuropil (Nadler et al., 1978; Sperk et al., 1983). The entorhinal cortex, piriform cortex, frontal
cortex, and medial thalamic nuclei are also subject to degrees of KA-induced degeneration
(Nadler et al., 1978; Kohler and Schwarcz, 1983; Sperk et al., 1983).

Figure 1.6. Photomicrograph illustrating the effects of (A) saline versus (B) kainic acid on CA1
hippocampal pyramidal neurons (40X magnification). Twenty-four hours following systemic
administration, saline-treated neurons are healthy and densely packed with rounded borders and
prominent nucleoli. Neurons damaged by kainic acid appear pyknotic and shriveled with darkstaining somata and shrunken processes.
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Kainate-induced death of hippocampal neurons is likely due to the sustained release of
glutamate during recurrent seizures (Coyle et al., 1981; Ben-Ari, 1985; Ben-Ari and Cossart,
2000) and subsequent increases in intracellular Ca2+ levels (Hori et al., 1985; Sun et al., 1992).
Excessive accumulation of glutamate in the synapse will activate post-synaptic glutamate
receptors, resulting in Ca2+ influx. Calcium accumulation is mediated predominantly by the
NMDA receptor, but AMPA or kainate receptors may also contribute to rises in intracellular
Ca2+ (Choi, 1992). The pathologic energy demands of repeated seizures lead to impairment of
Ca2+ sequestration and extrusion systems, contributing to Ca2+ elevations (see Tymianski and
Tator, 1996). Calcium homeostasis may be further disrupted by the release of Ca2+ from internal
stores, activation of certain enzymes (such as calpains and phospholipases), and changes in
immediate early gene expression. Glutamate efflux from injured neurons may further exacerbate
excitotoxic cascades (Choi, 1992).
Glucocorticoid modulation of kainic acid excitotoxicity
Glucocorticoids exacerbate KA toxicity (Sapolsky, 1985, 1986a, b; Sapolsky et al., 1988;
Packan and Sapolsky, 1990; Stein-Behrens et al., 1994a), making KA administration an excellent
model for studying ACR effects on neuronal viability. Glucocorticoids intensify KA-induced
accumulation of extracellular glutamate (Stein-Behrens et al., 1992; Stein-Behrens et al., 1994b)
and KA-induced calcium elevations (Elliott and Sapolsky, 1992, 1993). Chronic exposure to
glucocorticoids also impairs antioxidant defenses in response to KA (McIntosh et al., 1998a) and
increases the electophysiological sensitivity to KA in hippocampal neurons (Talmi et al., 1995).
In addition, glucocorticoids influence immediate early gene responses to KA (Unlap and Jope,
1995a) and exacerbate KA-induced spectrin proteolysis (Elliott et al., 1993; Lowy et al., 1994).
Glucocorticoids may also influence neuronal viability to KA via genomic mechanisms.
Kainate administration results in the altered expression of a multitude of genes, including: cell
survival/death genes (bcl-2, bax, p53, KROX-20, COX-2, cyclin D1, and GADD45) (Sakhi et
al., 1994; Gillardon et al., 1995; Vreugdenhil et al., 1996; Zhu et al., 1997; Hashimoto et al.,
1998; Timsit et al., 1999), transcription factors (AP-1 and NFκB) (Kaminska et al., 1994;
Pennypacker and Hong, 1995; Won et al., 1999), neurotrophic factors [BDNF and nerve growth
factor (NGF)] (Ballarin et al., 1991; Gall et al., 1991; Hashimoto et al., 1998), neuropeptides
(Pennypacker and Hong, 1995; Friedman, 1997), heat shock proteins (Zhang et al., 1997;
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Hashimoto et al., 1998), immediate early genes (Honkaniemi and Sharp, 1999), GABA-A
receptor subunits (Tsunashima et al., 1997), and countless others. Altered gene expression is
likely to influence cellular response to KA toxicity; accordingly, glucocorticoid modulation of
gene expression may modulate cell survival.

Experiments in the current thesis focus on

glucocorticoid regulation of members of the Bcl-2 family, p53, and neurotrophins BDNF and
NT-3, all of which have been implicated in KA-induced neuronal death (see below).
Regulators of cell survival and death
Members of the bcl-2 family of genes are critical regulators of cell viability. Interactions
between pro-survival genes, including bcl-2, bcl-xL, and bcl-w, and pro-death genes, such as bax
and bad, are thought to influence cellular susceptibility to necrotic and apoptotic death (Oltvai et
al., 1993; Korsmeyer, 1995; Merry and Korsmeyer, 1997). Bcl-2 family members influence cell
survival via multiple mechanisms including stabilization of mitochondria and interference with
cell death pathways (see below).
A key event associated with cell death is the opening of a large conductance channel called
the mitochondrial permeability transition pore. Permeability transition can be induced by a
number of stimuli, including sustained increases in intracellular Ca2+ levels, oxidative stress,
caspase activation (see below), uncoupling of the respiratory chain, and modification of the Bcl2 complex (Green and Reed, 1998). Opening of the nonselective permeability transition pore
allows molecules up to approximately 1.5 kD to pass through the mitochondrial inner membrane
into the matrix. The loss of inner membrane selectivity causes collapse of the mitochondrial
transmembrane potential and dissipation of the H+ gradient, resulting in the uncoupling of the
electron transport chain, a decrease in ATP production, and an increase in production of reactive
oxygen species. In addition, permeability transition pore opening causes release of caspaseactivating proteins such as cytochrome c and apoptosis-inducing factor (AIF) into the cytoplasm,
promoting apoptosis [see (Kroemer et al., 1997; Green and Reed, 1998)].
Mitochondrial release of cytochrome c promotes apoptosis by initiating protease cascades
programmed to dismantle the cell (Eldadah and Faden, 2000).

Cytochrome c facilitates

interaction between apoptotic protease activating factor-1 (Apaf-1) and procaspase-9 (Li et al.,
1997; Zou et al., 1997). Subsequent processing yields caspase-9, which activates “executioner”
caspases such as caspase-3 (Li et al., 1997; Pan et al., 1998b). Caspase-3 cleaves ICAD, the
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inhibitor of CAD, a caspase-activated deoxyribonuclease (Enari et al., 1998; Sakahira et al.,
1998). Once released from ICAD inhibition, CAD is responsible for internucleosomal DNA
degradation characteristic of apoptosis (Enari et al., 1998; Sakahira et al., 1998).
Conditions favoring apoptosis trigger bax translocation from the cytoplasm to mitochondrial
membranes (Green and Reed, 1998), promoting the release of cytochrome c from the
intramembranous compartment (Jurgensmeier et al., 1998). Anti-apoptotic proteins such as Bcl2 and Bcl-xL may inhibit apoptosis by preventing molecules such as Apaf-1 from activating
caspases (Pan et al., 1998a). Bcl-2 can also prevent mitochondrial permeability transition (Green
and Reed, 1998), the release of cytochrome c (Kluck et al., 1997; Yang et al., 1997), and the
release of AIF from mitochondria (Green and Reed, 1998), each of which could prevent caspase
activation. Although the functional significance is not fully understood, Bcl-2 family members
can also form cation-selective pores, which could speculatively influence ion transport, regulate
volume of the matrix space, control pH in the intermembrane space, or induce permeability
transition in mitochondria (Green and Reed, 1998). In addition, Bcl-2 acts at cell nuclei (Marin
et al., 1996), endoplasmic reticula (He et al., 1997), and mitochondria (Green and Reed, 1998) to
influence subcellular Ca2+ distribution. Whether the many effects of Bcl-2 are separate functions
or consequences of Bcl-2 regulation of a single cell death process remains uncertain.
Accumulating evidence supports a role for bcl-2 family members in modulating neuronal
viability after KA-induced seizure. Systemic KA administration decreases bcl-2 mRNA levels in
rat hippocampus (McCullers and Herman, 1998) (Chapter Two) and Bcl-2 immunoreactivity in
mouse hippocampus and cortex (Gillardon et al., 1995). In contrast, systemic KA increases bax
mRNA levels in rat hippocampus (McCullers and Herman, 1998; Lopez et al., 1999) (Chapter
Two) and mouse brain (Gillardon et al., 1995). Increased Bcl-w expression has also been
observed in rat hippocampus and piriform cortex following KA microinjection into the amygdala
(Henshall et al., 2001). Bcl-2 promotes neuronal survival of KA insult, as Bcl-2 overexpression
with viral vectors protects hippocampal neurons against KA toxicity in culture and in vivo
(Phillips et al., 2000). Furthermore, KA-induced degeneration is attenuated in Bax-deficient
cultured motor neurons (Bar-Peled et al., 1999), demonstrating Bax participation in KA-induced
cell death.
The p53 tumor-suppressor gene has been described as a guardian of the genome. In response
to DNA damage, the transcription factor induces either growth arrest or apoptosis depending
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upon the cell type, environment, and expression of other regulatory factors. In either scenario,
the end result is the genetic death of the damaged cell, preventing potential neoplastic risk (Evan
and Littlewood, 1998).

The mechanisms by which p53 promote apoptosis are not fully

delineated, but many studies indicate the involvement of repression or induction of specific
target genes such as bcl-2 and bax (Miyashita et al., 1994; Miyashita and Reed, 1995; Evan and
Littlewood, 1998). Transrepression of anti-apoptotic genes and non-transcriptional mechanisms
may also be involved (Evan and Littlewood, 1998). The signaling pathways by which insults
activate p53 are mostly unknown (Evan and Littlewood, 1998).
Experimental evidence suggests that p53 influences hippocampal vulnerability to KAinduced neuronal degeneration. P53 mRNA is induced in KA-sensitive brain regions including
hippocampus, amygdala, piriform cortex, and thalamus following systemic KA injection (Sakhi
et al., 1994) (Chapter Two), and nuclear accumulation of p53 protein has been observed in
degenerating neurons after KA administration (Sakhi et al., 1996). Furthermore, p53-deficient
mice (“knock-out” mice) exhibit little or no hippocampal cell loss after KA treatment (Morrison
et al., 1996; Xiang et al., 1996).
Neurotrophic factors (i.e. nerve growth factor, brain-derived neurotrophic factor,
neurotrophins-3 and 4/5, basic fibroblast growth factor, ciliary neurotrophic factor, and insulinlike growth factors) support neuronal differential and survival during development (Barde, 1989)
and may protect against select forms of neuronal injury (Lindsay et al., 1994; Mattson and
Scheff, 1994; Mocchetti and Wrathall, 1995). A variety of neurotrophic factors have been
reported to protect against injury resulting from physical, ischemic, excitotoxic, metabolic, and
oxidative insults (Mattson and Scheff, 1994; Mocchetti and Wrathall, 1995).

The

neuroprotective function of these factors is proposed to involve enhanced maintenance of Ca2+
homeostasis and free radical metabolism (Mattson and Scheff, 1994).
Several studies have examined the involvement of two members of the neurotrophin family,
brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3), in relation to KA
excitotoxicity in hippocampus. Intrahippocampal (Ballarin et al., 1991) or systemic (DugichDjordjevic et al., 1992; Lee et al., 1997) KA administration dramatically increases hippocampal
BDNF mRNA levels. Levels of BDNF mRNA remain elevated for as long as two weeks
following intracranial ventricular injection of KA (Garcia et al., 1997a). Increased BDNF
protein levels have also been demonstrated following systemic KA administration (Rudge et al.,
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1998; Katoh-Semba et al., 1999). In contrast, NT-3 mRNA levels are decreased following
systemic (Lee et al., 1997; Katoh-Semba et al., 1999) or intracranial ventricular (Garcia et al.,
1997a) KA administration, with decreases lasting up to two weeks post-injection in the latter
model (Garcia et al., 1997a).

NT-3 protein levels correspond with altered mRNA levels,

decreasing following systemic KA injection (Katoh-Semba et al., 1999). Experiments indicate
that BDNF and NT-3 protect cultured rat hippocampal, septal, and cortical neurons against
damage induced by glucose deprivation or glutamate neurotoxicity by attenuating harmful rises
in intracellular Ca2+ levels (Cheng and Mattson, 1994).

BDNF also protects cultured rat

cerebellar granule neurons against glutamate neurotoxicity (Lindholm et al., 1993). In contrast, a
study examining the effects of in vivo intrahippocampal neurotrophin administration reports no
neuronal protection against KA toxicity with NT-3 infusion and exacerbation of KA-induced
injury in CA3 with BDNF administration (Rudge et al., 1998).
Controlled cortical impact as a model of traumatic brain injury
Hypothalamic-pituitary-adrenal abnormalities are prevalent in human cases of head injury
(King et al., 1970; Pentelenyi and Kammerer, 1984; Chiolero and Berger, 1994; Lieberman et al.,
2001), indicating the urgent need for research examining the physiological effects of
glucocorticoid secretion after traumatic brain injury (TBI). Synthetic glucocorticoid steroids
such as methylprednisolone have been extensively used in the clinical treatment of central
nervous system trauma.

In 1990, the American National Acute Spinal Cord Injury Study

demonstrated significant benefits of high-dose methylprednisolone in the treatment of human
spinal cord injury (Bracken et al., 1990). However, the utility of these compounds with respect
to brain injury requires further evaluation (see McIntosh et al., 1998b).

Not surprisingly,

neuroprotection conferred by methylprednisolone is thought to be independent of hormonal
(receptor-mediated) glucocorticoid activities; rather, the primary neuroprotective mechanism of
methylprednisolone is hypothesized to be the inhibition of oxygen free-radical induced lipid
peroxidation via direct membrane effects (Hall et al., 1992). While the nonhormonal effects of
exogenous synthetic steroids have been researched extensively, the physiological role for
endogenous glucocorticoids after TBI remains largely unexamined. Increased cortisol levels
reported with human TBI (King et al., 1970; Pentelenyi and Kammerer, 1984) emphasize the

25

potential importance of receptor-mediated glucocorticoid effects on neuronal viability after
trauma.
Many animal models of mechanical brain injury have been developed in an attempt to
reproduce aspects of human closed-head injury. Of these, several commonly used techniques
are: fluid percussion, which produces brain injury by the rapid injection of fluid into the closed
cranial cavity (Dixon et al., 1987); closed head injury, in which a weight-drop device delivers a
standard blow to the skull (Shapira et al., 1988); and the cortical impact model, which uses a
pneumatic impactor to deliver a controlled impact to the exposed dura, with measurable velocity
and cortical deformation (Dixon et al., 1991). Experiments in the present thesis employ the
controlled cortical impact (CCI) model of TBI in conjunction with ACR antagonist treatments in
order to study ACR effects on hippocampal neuron viability following TBI.
Controlled cortical impact pathology
Traumatic injury of the human brain causes neuronal loss in regions including cortex,
hippocampus, thalamus, and cerebellum (Adams et al., 1985; Kotapka et al., 1992; Ross et al.,
1993). Neuronal degeneration caused by TBI is the product of direct mechanical insult (primary
injury) and delayed pathological events including ion disequilibration, free radical formation,
membrane damage, protease activation, and cytoskeletal disruption (secondary injury) (Faden,
1993).

The delayed component of TBI pathology is of great significance as it provides

opportunity for therapeutic intervention after injury.

The pattern of neuronal loss in

experimentally injured rat brain mimics that of human TBI, with neuronal degeneration observed
in cortical areas overlying the evolving contusion, in hippocampus, and in lateral thalamus
(Sutton et al., 1993; Dietrich et al., 1994; Hicks et al., 1996). Dark, shrunken neurons and
swollen astrocytes can be detected in the acute phase, as early as ten minutes following injury
(Hicks et al., 1996). With the controlled cortical impact model at moderate severity, neuronal
loss in CA3 is evident by one hour after injury (Baldwin et al., 1997). Furthermore, there is no
significant difference in the percentage of surviving CA3 neurons estimated 24 hours or 30 days
post-injury, indicating that neuronal loss is rapid and complete by 24 hours (Baldwin et al.,
1997). Moderate levels of experimental TBI result in neuronal death by both necrosis and
apoptosis, with the greatest loss caused by necrosis (Raghupathi et al., 2000; Zipfel et al., 2000).
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Secondary neuronal degeneration following traumatic insult is driven by an array of
physiological and biochemical changes.

Excessive glutamate release (Faden et al., 1989;

Bullock and Fujisawa, 1992), increased intracellular Ca2+ levels (Young, 1992; Nilsson et al.,
1993; McIntosh et al., 1998c), mitochondrial dysfunction (Sullivan et al., 1998; Sullivan et al.,
1999), metabolic changes (Hovda et al., 1992), tissue edema (Wahl et al., 1988), lipid
peroxidation (Braughler and Hall, 1992), free radical formation (Lewen et al., 2000), vascular
disruption (Cortez et al., 1989), neurochemical alterations (Hayes et al., 1992), inflammation
(Feuerstein et al., 1997), astroglial responses (Cortez et al., 1989), axonal injury (Povlishock and
Christman, 1995), proteolysis (Kampfl et al., 1997), activation of cell death pathways (Beer et
al., 2000; Raghupathi et al., 2000), and altered gene expression (Mattson and Scheff, 1994;
Hayes et al., 1995; Raghupathi et al., 2000) are among the many factors identified as contributors
to trauma-induced degeneration (see Faden, 1993).
Glucocorticoid modulation of traumatic brain injury
Many factors contributing to secondary neuronal degeneration following TBI are likely
influenced by glucocorticoids.

Glucocorticoids reduce edema (Xu et al., 1992), influence

neurotransmitter systems (Meijer and de Kloet, 1998), reduce inflammation (De Bosscher et al.,
2000), and interact with cell death pathways (Reagan and McEwen, 1997). Steroid hormones
also prevent lipid hydrolysis and the subsequent formation of oxygen free radicals, as noted
above (Hall et al., 1992). Furthermore, glucocorticoids exacerbate cognitive deficits associated
with experimental TBI (Hicks et al., 1993; White-Gbadebo and Hamm, 1993; Smith et al., 1994;
Scheff et al., 1997). Experiments in the current thesis focus on glucocorticoid and traumainduced regulation of viability-related genes, specifically members of the bcl-2 family and
tumor-suppressor p53.
Regulators of cell survival and death
Bcl-2 family members are critical regulators of cell viability, and an increasing body of
evidence suggests that bcl-2 related proteins control neuronal survival following TBI. Bcl-2
expression increases in injured human brain (Clark et al., 1999) and in rat hippocampal and
cortical neurons surviving cortical impact with secondary hypoxia (Clark et al., 1997). In
contrast, bcl-2 expression is reported to decrease in rat cortical neurons following closed head
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injury (Lu et al., 2000). A neuroprotective role for Bcl-2 after TBI has been supported by studies
demonstrating reduced neuronal loss in injured cortex and hippocampus of Bcl-2 overexpressing
mice (Raghupathi et al., 1998; Nakamura et al., 1999).

Bax may also participate in the

regulation of TBI-induced neuronal death, as bax translocation to nuclei of injured cortical and
hippocampal neurons has been reported forty-eight hours after cortical contusion (Kaya et al.,
1999).
P53, a regulator of bcl-2 and bax expression (Miyashita et al., 1994), is also associated with
experimental TBI in the rat. Induction of p53 mRNA has been observed in cortex, hippocampus,
and thalamus following lateral fluid-percussion injury (Napieralski et al., 1999), and
translocation of p53 proteins to nuclei of injured neurons has been reported using the controlled
cortical impact model (Kaya et al., 1999). Neuronal apoptosis in thalamus is attenuated in p53 /- mice (Martin et al., 2001), but a study measuring cortical lesion volume after controlled
cortical impact in p53 -/- mice reported no significant differences compared to wild-type
(Tomasevic et al., 1999).
Several studies suggest that neurotrophic factors may also influence hippocampal neuron
survival following TBI. Nerve growth factor mRNA levels are increased in dentate gyrus after
injury by lateral fluid percussion (Truettner et al., 1999), while NT-3 mRNA levels are decreased
(Hicks et al., 1997). In addition, increased hippocampal BDNF mRNA levels are observed
following injury with CCI (Yang et al., 1996) and lateral fluid percussion (Hicks et al., 1997;
Truettner et al., 1999) models of TBI, suggesting the potential for enhanced neuronal survival
due to altered neurotrophin expression.

In support of a neuroprotective role for BDNF

expression after fluid percussion injury, BDNF mRNA levels are decreased in cortical regions
containing degenerating neurons, generally unchanged in adjacent areas, and increased in more
remote regions such as piriform cortex (Hicks et al., 1999).

However, in a recent study

intrahippocampal infusion of BDNF did not improve measures of neuronal loss, neuromotor
function, learning, or memory following lateral fluid percussion injury (Blaha et al., 2000).
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Chapter Two: Mineralocorticoid receptors regulate bcl-2 and p53 mRNA
expression in hippocampus
Introduction
Glucocorticoids regulate gene expression in hippocampal neurons through mineralocorticoid
receptor (MR) and glucocorticoid receptor (GR) proteins. MR binds glucocorticoids with high
affinity but low capacity, whereas GR binds with low affinity and high capacity (Reul and de
Kloet, 1985).

These differences in binding efficacy allow MR and GR to regulate gene

expression in a concentration-dependent manner; MR is predominantly active at low
concentrations of glucocorticoids, while GR becomes increasingly bound and dominant at higher
glucocorticoid concentrations (Reul and de Kloet, 1985). MR activity at low glucocorticoid
levels is associated with increased cell excitability (Joels and de Kloet, 1990), long-term
potentiation (Pavlides et al., 1995), and dentate gyrus (DG) granule cell survival (Woolley et al.,
1991). In contrast, high levels of glucocorticoids acting mainly through GR have been shown to
reduce long-term potentiation (Pavlides et al., 1993), shrink hippocampal pyramidal cell
dendrites (Woolley et al., 1990), and exacerbate damaging effects of toxic insults (Sapolsky et
al., 1988; Packan and Sapolsky, 1990). Thus, MR and GR seem to promote differential cellular
effects; MR appears to enhance and GR appears to compromise neuronal viability.
The influence of MR and GR on survival of hippocampal neurons is likely exerted at the
level of gene regulation. To address the role of the MR in this regulation, we tested the effect of
spironolactone (SPIRO), a specific, competitive MR antagonist (Sutanto and de Kloet, 1991), on
basal and kainic acid (KA) stimulated expression of mRNAs associated with apoptosis or
neuronal survival.

Messenger RNAs include those that encode:

1) bcl-2, an inhibitor of

apoptosis which is down-regulated by KA (Gillardon et al., 1995); 2) bax, a death-inducing
member of the bcl-2 gene family which is up-regulated by KA (Gillardon et al., 1995); 3) p53, a
tumor-suppressor which is induced by KA-related DNA damage (Sakhi et al., 1994); 4) brainderived neurotrophic factor (BDNF), a neurotrophin which is induced by KA excitotoxicity
(Ballarin et al., 1991); and 5) neurotrophin-3 (NT-3). To investigate the hypothesis that MR
promotes neuroprotective gene activity, we evaluated the effects of MR blockade and KA
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treatment by in situ hybridization analysis of mRNA expression in CA1, CA3, and DG of the rat
hippocampal formation.
Materials and Methods
Animal treatment and tissue preparation
All animal handling and protocols were approved by the University of Kentucky IACUC.
Young adult male Sprague-Dawley rats were subcutaneously injected twice daily, in morning
and afternoon, with MR antagonist spironolactone (50 mg/kg) or sesame oil vehicle. Treatment
continued for three days until a total of five injections were administered. On day three, two
hours after the final morning injection, half of each group received intraperitoneal injection of
kainic acid (12 mg/kg), while the remaining half received 0.9% saline vehicle. Rats were
monitored for 8 hours following KA injections; only animals exhibiting behavioral changes
indicative of KA seizures as described previously (Sperk et al., 1983) were included in the study.
Animals were decapitated on day four, twenty-four hours after onset of kainic acid-induced
seizure activity. Brains were rapidly removed and frozen in isopentane (Sigma) cooled to -30 o
to -40o C on dry ice. Tissue was sectioned (16 um) with a Bright-Hacker cryostat, thaw-mounted
onto Ultrastick Slides (Becton Dickinson), and stored at -20 o C.
In situ hybridization
Assessment of mRNA expression was accomplished using probes specific for 1) bcl-2, 2)
bax, 3) p53, 4) BDNF, and 5) NT-3. Probes were labeled by standard in vitro transcription,
using
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P-UTP, according to previously published methods (Seroogy and Herman, 1996).

Frozen tissue sections removed from a -20 o C freezer were placed in 4% paraformaldehyde for
10 min. Slides were rinsed with 5mM KPBS, 5mM KPBS with 0.2% glycine, and again with
5mM KPBS. Following 10 min in 0.1 M TEA with 0.25% acetic anhydride and rinses in 0.2X
SSC, sections were dehydrated. Labeled probes were added to a hybridization buffer containing
50% formamide. 50 uL (1 x 106 cpm) of diluted probe were applied to each slide. Slides were
coverslipped, placed in moistened chambers, and incubated overnight at 55

o

C. Following

hybridization, coverslips were removed in 2X SSC, rinsed once in fresh 2X SSC, rinsed 3X in
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0.2X SSC for 10 min. per wash, followed by a 1 hour wash in 0.2X SSC at 60

o

C. After

dehydration, slides were exposed for 14 - 21 days to Kodak BioMAX film.
Data analysis
Densitometric measurements were taken from subfields CA1, CA3, and dentate gyrus using
NIH Image 1.55 software for Macintosh. Data were analyzed by two-way ANOVA, with
planned comparisons used to distinguish significance of KA and SPIRO effects.

The

relationship between bax and p53 mRNAs was assessed by regression analysis.
Results
Figure 2.1 illustrates expression of bcl-2, bax, and p53 in hippocampus of saline- and KAtreated rats. Bcl-2 mRNA levels were significantly affected by SPIRO (F(1, 25) = 4.305; p <
0.05) and KA (F(1, 25) = 5.845; p < 0.05) in CA1 and by KA in CA3 (F(1,25) = 6.468; p <
0.05). Planned comparisons indicate that SPIRO decreased basal bcl-2 mRNA levels in CA1 and
CA3 of saline-treated subjects (p < 0.05). Kainic acid significantly decreased bcl-2 mRNA
levels in CA1 (p < 0.05) and CA3 (p < 0.01) of oil-treated subjects (Figure 2.2).
Kainic acid treatment significantly influenced bax mRNA expression in CA1 (F(1, 12) =
5.555; p < 0.05) and CA3 (F(1, 24) = 8.049; p < 0.01) (Figure 2.3). Planned comparisons
revealed that following KA injection, bax mRNA expression significantly increased in CA1 (p =
0.05) of SPIRO-treated animals and in CA3 (p < 0.05) of oil-treated animals. MR blockade had
no significant effect on bax mRNA expression.
Spironolactone (F(1,20) = 4.481; p < 0.05) and KA treatment (F(1, 20) = 15.819; p < 0.001)
elicited significant main effects on p53 mRNA expression in CA3, the only hippocampal region
in which p53 was observed in consistently quantifiable amounts (Figure 2.4). Kainic acid
significantly increased p53 mRNA levels in CA3 of oil-treated animals (p < 0.001), while
SPIRO pre-treatment significantly attenuated this increase (p < 0.05).
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Figure 2.1. Photomicrographs illustrating bcl-2 (A, B), bax (C, D), and p53 (E, F) mRNA
distribution in hippocampus of saline- (A, C, E) and KA-treated (B, D, F) rats. KA decreased
bcl-2 mRNA expression in CA1 and CA3, increased bax mRNA expression in CA3, and
increased p53 mRNA expression in CA3.
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Figure 2.2. Effects of MR blockade and kainic acid on bcl-2 mRNA expression in hippocampus.
MR blockade with SPIRO significantly decreased basal bcl-2 mRNA expression in CA1 and
CA3 of saline-treated animals (*p < 0.05). KA decreased bcl-2 mRNA expression in CA1 and
CA3 of oil-treated animals (‡p < 0.05).
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Figure 2.3. Effects of MR blockade and kainic acid on bax mRNA expression in hippocampus.
Kainic acid (KA) significantly increased bax mRNA expression in CA1 of SPIRO-treated
animals and in CA3 of oil-treated animals (‡p < 0.05).
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Figure 2.4. Effects of MR blockade and kainic acid on p53 mRNA expression in hippocampus.
Kainic acid significantly increased p53 mRNA levels in CA3 (‡p < 0.05). MR blockade with
SPIRO significantly attenuated the KA-induced increase (*p < 0.05).

Kainic acid treatment significantly altered BDNF mRNA levels in CA1 (F(1, 23) = 26.952; p
< 0.0001) and CA3 (F(1, 23) = 13.511; p < 0.01); expression increased significantly (p < 0.05) in
CA1 and CA3 of both oil- and SPIRO-treated animals (Figure 2.5). NT-3 mRNA levels were
affected by KA in DG (F(1, 24) = 107.00; p < 0.0001), showing significant decreases in
expression in both oil- and SPIRO-treated animals (p < 0.0001) (Figure 2.6). MR blockade had
no significant effect on BDNF or NT-3 mRNAs.
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Figure 2.5.

Effects of MR blockade and kainic acid on brain derived neurotrophic factor

(BDNF) expression in hippocampus.

Kainic acid significantly increased BDNF mRNA

expression in CA1 and CA3 (‡p < 0.05).
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Figure 2.6. Effects of MR blockade and kainic acid on neurotrophin-3 (NT-3) expression in
hippocampus. KA decreased NT-3 mRNA expression in DG (‡p < 0.05).
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Discussion
Within the bcl-2 gene family, dimerization among death-repressing members, such as Bcl-2,
and death-inducing members, such as Bax, is thought to determine cellular response to apoptotic
signals. The ratio of life-promoting to death-promoting proteins determines if dimerization
favoring cell survival will occur (Oltvai et al., 1993). We report that MR blockade by SPIRO
decreases basal bcl-2 mRNA expression in CA1 and CA3, demonstrating that MR activity is
essential in maintaining normal levels of bcl-2 mRNA in these regions. This finding supports the
hypothesis that MR functions as a neuroprotective factor, as decreases in bcl-2 mRNA could lead
to the alteration of cellular Bcl-2/Bax ratios and predispose cells to apoptotic cell death. We also
report a decrease in bcl-2 mRNA expression in CA1 and CA3 of oil-treated animals with KA
administration, an effect previously demonstrated in mouse hippocampus (Gillardon et al.,
1995). Bcl-2 mRNA levels were similarly decreased in SPIRO and oil-treated animals after KAtreatment. Thus, whereas SPIRO pretreatment decreased bcl-2 mRNA levels in control rats, it
did not exacerbate decreases in bcl-2 mRNA expression induced by KA treatment. Overall, the
data suggest that MR modulates bcl-2 expression in hippocampus and may therefore play a role
in pyramidal cell survival.
The observed induction of bax mRNA expression in CA1 and CA3 following KA treatment
is consistent with previous studies (Gillardon et al., 1995). Notably, levels of bax mRNA did not
differ significantly between SPIRO or oil-treated groups prior to or following KA administration.
In combination with decreased bcl-2 mRNA expression, these results suggest a possible reduced
Bcl-2/Bax ratio, a scenario believed to favor the neuroendangering actions of Bax (Oltvai et al.,
1993).
In agreement with previous studies (Sakhi et al., 1994), we demonstrated that KA treatment
increases p53 mRNA levels in rat hippocampus. We additionally report that SPIRO attenuated
this KA-induced increase in CA3, indicating MR involvement in p53 mRNA expression under
these conditions. As accumulation of p53 is associated with induction of apoptosis (YonishRouach et al., 1991; Sakhi et al., 1996), these data suggest that, contrary in part to our principal
hypothesis, the MR may play a role in regulating both protective and endangering gene products.
Bax mRNA responses parallel those of p53 mRNA in this study. SPIRO appeared to
attenuate the KA-induced increase of bax mRNA in CA3 and also significantly reduced the KA
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induction of p53 mRNA in the same region. These changes in bax and p53 mRNA levels after
KA treatment are significantly correlated (r = 0.74; p < 0.05), indicating that the expression of
bax and p53 mRNAs are regulated in parallel. P53 is capable of inducing the human bax gene
(Miyashita and Reed, 1995) and is thought to participate in a signaling pathway involving bax
and bcl-2 that predisposes cells to apoptosis (Miyashita et al., 1994). For these reasons, the
similar responses observed in this study invite speculation that increased bax mRNA levels may
result from upregulation by p53. However, p53 overexposure has been shown to cause apoptosis
in hippocampal pyramidal neurons without bax induction (Jordan et al., 1997), so the possibility
remains that the increases in bax and p53 mRNA are not causally linked.
Consistent with previous reports (Ballarin et al., 1991), this study demonstrated that BDNF
mRNA levels increase in rat hippocampus following KA treatment. As elevated glucocorticoid
levels have been shown to decrease the expression of BDNF mRNA (Schaaf et al., 1997), this
induction is most likely a consequence of another aspect of KA excitotoxicity, although possibly
influenced by glucocorticoid input. In addition, NT-3 mRNA expression was decreased in DG
of animals receiving KA.

While neurotrophins are clearly susceptible to glucocorticoid

regulation, as demonstrated by previous studies (Chao and McEwen, 1994; Smith et al., 1995a),
there does not appear to be any differential regulation of BDNF or NT-3 mRNA with MR
blockade prior to or following excitotoxic insult with KA.
It should be noted that blockade of the MR may alter mRNA expression via activity of an
unopposed GR. Without the MR available to form MR-GR heterodimers and otherwise compete
with GR homodimers at the GC response element, an increase in GR-mediated transactivation
may underlie changes in transcriptional regulation. Overall, it is clear that MR blockade affects
bcl-2 and p53 mRNA levels, but whether this change is due to a loss of MR or increase in GR
activity remains to be determined.

Another important consideration is the substantial

hippocampal pyramidal cell loss that accompanies KA treatment after 24 hours. It is possible
that changes observed in bcl-2, bax, and p53 mRNAs could represent non-specific actions of
dying cells, rather than specific regulatory events, or possibly reflect changes in surviving cell
numbers.
Our current understanding of the function of GC receptors and cell viability is far from
complete. The MR likely participates in apoptosis regulation, but the present evidence does not
convincingly support an exclusively neuroprotective role.
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One problematic issue is the

complexity of receptor interaction involved. It is unclear at this time whether changes in mRNA
expression following MR blockade are attributable to an absence of MR activity or an
exaggerated presence of GR.

Based on the available data, it appears that MR promotes

protective gene induction under normal conditions, which may have important implications for
survival of pyramidal cells following injury.
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Chapter Three: Adrenocorticosteriod receptor blockade and excitotoxic
challenge regulate adrenocorticosteroid receptor mRNA levels in
hippocampus
Introduction
Glucocorticoids are steroid hormones that convey hypothalamic-pituitary-adrenal (HPA) axis
information throughout the body. Two types of adrenocorticosteroid receptors (ACRs) mediate
glucocorticoid action in brain: the mineralocorticoid receptor (MR) and the glucocorticoid
receptor (GR). Once the receptors bind glucocorticoid ligand, cortisol in humans and
corticosterone (CORT) in rodents, MR and GR act as transcription factors (Yamamoto, 1985) to
modulate genes controlling many physiological processes including development, metabolism,
memory, inflammation, immune function, and cell death (Munck et al., 1984; McEwen et al.,
1986).
Because the MR has greater affinity for binding CORT and the GR greater capacity, the MR
is mainly active at basal glucocorticoid concentrations while the GR is extensively bound during
periods of elevated glucocorticoid levels (Reul and de Kloet, 1985; Reul et al., 1987).
Predominant activation of the MR or GR at different CORT concentrations appears to have
opposing effects on neuronal viability in hippocampus, an area of MR and GR colocalization
(Reul and de Kloet, 1985; Herman et al., 1989a) that is particularly susceptible to glucocorticoidmediated effects. For example, activation of the MR protects hippocampal dentate gyrus (DG)
granule cells from adrenalectomy (ADX) induced death (Woolley et al., 1991). In contrast,
prolonged elevation of glucocorticoid levels, acting mainly through the GR, shrinks pyramidal
cell dendrites (Woolley et al., 1990), impairs calcium regulation (Elliott and Sapolsky, 1993),
and exacerbates neuronal insults (Sapolsky, 1985; Sapolsky and Pulsinelli, 1985; Sapolsky,
1986a; Sapolsky et al., 1988; Goodman et al., 1996; McIntosh and Sapolsky, 1996a). Thus,
evidence exists that the MR protects and the GR endangers hippocampal neurons.
Considering the differential effects of MR and GR on hippocampal cell survival, ACR
activation may be of critical importance in the cellular response to injury. To address this issue,
the present study is designed to investigate the roles of the MR and the GR in regulating ACR
expression and neuron viability under basal conditions and following excitotoxic insult. Subjects
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were pretreated with vehicle, the MR antagonist spironolactone (SPIRO), or the GR antagonist
mifepristone (RU486) and subsequently challenged with systemic injection of kainic acid (KA).
In situ hybridization was performed to assess the effects of ACR blockade and subsequent
challenge with KA on relative MR and GR mRNA levels. In addition, hippocampal neuronal
loss was evaluated following MR or GR blockade and KA insult to determine the role of ACRs
in hippocampal vulnerability to injury in vivo. The results of this study provide further evidence
for homo- and heterologous regulation of ACR expression and indicate that ACR mRNA
regulation is altered by glutamate receptor stimulation.
Materials and Methods
Subjects
Young adult male Sprague Dawley rats (Harlan Sprague Dawley, Inc., Indianapolis, IN)
weighing between 200-250 gm were maintained on a 12 hr light/dark cycle in an environment
with constant temperature, humidity, and ad libitum access to food and water. All animal
procedures were performed in accordance with the National Institutes of Health guidelines and
approved by the University of Kentucky Institutional Animal Care and Use Committee.
In vivo protocols
All rats were injected s.c. twice daily, in morning and afternoon, with propylene glycol
vehicle, MR antagonist spironolactone (SPIRO) (50 mg/kg) (Herman and Spencer, 1998)
(Sigma, St. Louis, MO), or GR antagonist RU486 (25 mg/kg) (Ratka et al., 1989) (Sigma).
Subjects were administered a final pretreatment injection at 900h on day three, followed by an
i.p. injection of either saline vehicle or kainic acid (KA) (12 mg/kg)(Sigma) at 1100h. Subjects
were monitored for seizure activity for 6h following KA injections, and only those displaying
behavioral changes indicative of KA intoxication (Sperk et al., 1983) were included in the study.
All animals were sacrificed on day 4 at 1200h, approximately 24h after seizure onset.
Animals processed for plasma CORT determination and in situ hybridization experiments
were killed by rapid decapitation. Brains were rapidly removed, frozen in isopentane cooled to –
40oC on dry ice, then stored at –80oC. Brains were later warmed to -20 oC, sectioned to 16 um
with a Bright-Hacker cryostat, thaw-mounted onto Ultrastick Slides (Becton Dickinson, Franklin
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Lakes, NJ), and stored at -20oC until processing for in situ hybridization. Trunk blood samples
were collected into heparinized tubes on ice, and plasma was separated by centrifugation and
stored at –20oC.
Animals processed for cell counts received a lethal dose of sodium pentobarbitol (Butler,
Columbus, OH)(150mg/kg) before undergoing transcardial perfusion with 0.9% saline followed
by 4% paraformaldehyde. Brains were removed, post-fixed in 4% paraformaldehyde overnight,
then placed in 30% sucrose at 4oC for 24h. Brains were then stored in 70% ethanol until
embedded in paraffin.
Radioimmunoassay
Radioimmunoassay was performed to measure plasma CORT concentration. A doubleantibody rat corticosterone kit (ICN Biochemicals, Costa Mesa, CA) was used to determine 125Ilabeled CORT levels. Due to a skewed distribution of CORT values, we performed a log
transformation of the data before analysis by two-way ANOVA. Data shown in Table 3.1
represent actual CORT values listed as mean ± standard error. Two-way ANOVA was used to
analyze log-transformed CORT values for main effects (of antagonist groups and KA treatment)
and their interactions. Pairwise comparisons were made to determine significance of individual
group effects within treatments and vice versa using the Student-Newman-Keuls test, with
significance set at p ≤ 0.05.
In situ hybridization
Antisense riboprobes specific for rat MR (550 bp, complementary to the coding region and 3’
untranslated region of rat MR mRNA) and rat GR (456 bp, complementary to the coding region
and 3’ untranslated region of rat GR mRNA) were labeled according to previously published
methods (Seroogy and Herman, 1996) by standard in vitro transcription using [35S]UTP. Tissue
sections removed from a –20oC freezer were fixed in 4% paraformaldehyde for 10 min. Slides
were then rinsed sequentially in the following solutions: 5 mM KPBS, 5 mM KPBS with 0.2%
glycine, 5mM KPBS, 0.1 M triethanolamine with 0.25% acetic anhydride, 0.2X SSC, and graded
alcohols. Labeled probes were added to a hybridization buffer containing 50% formamide, and
diluted probe (50 ul containing 1x 106 c.p.m.) was applied to each slide.
coverslipped, placed in moistened chambers, and incubated overnight at 55oC.
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Slides were
Following

hybridization, slides were rinsed in 2X SSC and incubated in 0.2X SSC at 60oC for 1 hr. Slides
were then dehydrated and exposed for 14 days to Kodak BioMAX xray film.
Autoradiographic images were digitized with NIH Image 1.62 software for Macintosh. Based
on morphological criteria, regions CA1, CA3, and DG of the hippocampal formation were
manually sampled for densitometric analysis.

The mean gray level of an unhybridized

(background) area from each section was subtracted from sampled regions to arrive at corrected
gray level. The data were then expressed as a percentage of control (vehicle/saline) and analyzed
by two-way ANOVA within each subregion.

Pairwise comparisons were made using the

Student-Neuman-Keuls test to determine significant effects of groups within treatments and vice
versa, with significance set at p ≤ 0.05. Data in Figures 3.2 and 3.3 are presented as percentage
of vehicle/saline control ± standard error.
Cell counts
Nissl-stained sections of perfused tissue were examined by light microscopy for undamaged
neurons in the CA1 and CA3 pyramidal layers of dorsal hippocampus approximately 3mm
posterior to bregma. Cell counts were not performed in dentate gyrus because no damaged
granule cells were observed and because of the general insensitivity of this subregion to KA
(Sperk et al., 1983).

Neurons identified by round, healthy-looking somata and prominent

nucleoli were counted by an observer blinded to the experimental design. In preparation for cell
counts, perfused, paraffin-embedded, slide-mounted tissue was deparaffinized in xylene for 10
min, hydrated through graded alcohols, and immersed in cresyl violet Nissl stain for 5 min.
Slides were then rinsed briefly in dH2O, dehydrated through graded alcohols, cleared in xylene
for 5 min, and coverslipped with DPX mountant.
To obtain cell counts, numbers of neurons with identifiable nucleoli were recorded from a
100 um2 field. Counts were performed in three sections per subject, and within each section,
three fields were counted from CA1 and from CA3 then averaged to calculate subregional means
per section. Subregional means from each section were then averaged to determine mean
numbers of live CA1 and CA3 neurons for each animal.

Cell counts were analyzed for

significant effects using two-way ANOVA. Post hoc comparisons were made using the StudentNewman-Keuls test, with significance set at p ≤ 0.05. Data in Table 3.2 are presented as mean
cell number per 100 um2 field ± standard error.
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Results
Effects of ACR blockade and KA on CORT levels
Two-way ANOVA indicates that 24h post-insult, KA significantly increased CORT levels
[F(1,42) = 65.42; p ≤ 0.05) (Table 3.1).

Post hoc comparisons indicate that KA-induced

elevations in CORT levels were significant in all pretreatment groups. ACR antagonists also
produced a significant main effect on CORT levels [F(2,42) = 5.96; p ≤ 0.05]. In saline-treated
animals, MR blockade with SPIRO increased basal CORT levels, while GR antagonist RU486
decreased basal CORT levels relative to vehicle-pretreated animals.
Table 3.1.

Effects of adrenocorticosteroid receptor blockade and kainic acid on plasma

corticosterone levels (ng/ml)
Group
VEHICLE
SPIRO
RU486
VEHICLE
SPIRO
RU486

Treatment
SALINE
SALINE
SALINE
KA
KA
KA

N
11
7
6
11
6
7

Mean CORT Level
78.35 ± 20.89
137.01 ± 23.24a
23.93 ± 5.07 a
332.03 ± 59.42b
275.43 ± 53.35b
325.85 ± 69.87b

SPIRO = MR antagonist spironolactone
RU486 = GR antagonist mifepristone
KA = excitotoxin kainic acid
a
p ≤ 0.05 as compared to vehicle/saline subjects (effect of antagonist)
b
p ≤ 0.05 as compared to saline subjects within the same pretreatment
group (effect of kainic acid)
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Effects of ACR blockade and KA on MR and GR mRNA levels
Relative changes in ACR mRNA levels were determined by film densitometry following in
situ hybridization with MR and GR-specific riboprobes (see Methods, Figure 3.1).

Figure 3.1. Photomicrographs illustrating the effects of saline (A,C) and kainic acid (B,D) on
MR (A,B) and GR (C,D) mRNA levels in hippocampus of vehicle-pretreated rats. Panels A,B:
Kainic acid decreases MR mRNA levels in CA1 and CA3. Panels C,D: Kainic acid decreases
GR mRNA levels in dentate gyrus.
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Pretreatment with ACR antagonists significantly affected MR mRNA levels in hippocampal
subregions CA1 [F(2,42) = 5.51; p ≤ 0.05], CA3 [F(2,42) = 6.58; p ≤ 0.05], and DG [F(2,42) =
4.80; p ≤ 0.05] (Figure 3.2). MR antagonist SPIRO increased MR mRNA signal in CA1, CA3,
and DG of saline-treated animals, while GR antagonist RU486 had no significant effects on basal
MR mRNA levels. KA effects on MR mRNA levels were significant in CA1 [F(1,42) = 83.43; p
≤ 0.05] and CA3 [F(1,42) = 60.62; p ≤ 0.05]. KA decreased MR mRNA levels in regions CA1
and CA3 of all pretreatment groups.

Figure 3.2.

Effects of ACR blockade and KA treatments on MR mRNA levels in rat

hippocampus. Semi-quantitative analysis expressed as percentage of control (vehicle/saline)
corrected gray level. SPIRO significantly increased basal MR mRNA levels in CA1, CA3, and
DG of saline-treated animals. KA significantly decreased MR mRNA levels in CA1 and CA3 of
all pretreatment groups. [a p ≤ 0.05 as compared to vehicle/saline animals (effect of antagonist
group).

b

p ≤ 0.05 as compared to saline animals within same pretreatment group (effect of KA

treatment).]
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Two-way ANOVA demonstrates a significant group/treatment interaction effect on GR
mRNA levels in region CA3 [F(2,42) = 5.16; p ≤ 0.05] (Figure 3.3). SPIRO and RU486
significantly increased basal GR mRNA in region CA3, but no significant interaction effects
within post hoc comparisons were observed. Main effects of KA treatment on GR mRNA levels
were significant in regions CA1 [F(1,42) = 7.27; p ≤ 0.05], CA3 [F(2,42) = 24.72; p ≤ 0.05], and
DG [F(2,42) = 91.25; p ≤ 0.05]. KA induced significant decreases in GR mRNA signal in CA1
of RU486 animals, in CA3 of SPIRO and RU486-treated animals, and in DG of all pretreatment
groups.

Figure 3.3.

Effects of ACR blockade and KA treatments on GR mRNA levels in rat

hippocampus. Semi-quantitative analysis expressed as percentage of control (vehicle/saline)
corrected gray level. SPIRO and RU486 significantly increased basal GR mRNA levels in CA3
of saline-treated animals. KA decreased GR mRNA levels in CA1 of the RU486 pretreatment
group, in CA3 of SPIRO and RU486 pretreatment groups, and in DG of all groups. [a p ≤ 0.05 as
compared to vehicle/saline animals (effect of antagonist group).

b

animals within same pretreatment group (effect of KA treatment).]

48

p ≤ 0.05 as compared to saline

Effects of ACR blockade and KA on hippocampal neuron viability
Neurons were counted to determine the effects of ACR antagonists on hippocampal neuron
viability in CA1 and CA3 following KA challenge (see Methods) (Table 3.2). Neither ACR
blockade nor KA significantly affected the number of CA1 pyramidal neurons. Kainic acid
produced a significant main effect on the number of viable neurons in CA3 [F(1,22) = 6.35; p ≤
0.05]. The excitotoxin decreased live cell numbers in CA3 of SPIRO-pretreated subjects, but
post hoc comparisons indicate no significant effects of antagonist pretreatment.
Table 3.2. Effects of adrenocorticosteroid receptor blockade and kainic acid
on hippocampal neuron viability

Region
CA1

CA3

Group
VEHICLE
SPIRO
RU486
VEHICLE
SPIRO
RU486
VEHICLE
SPIRO
RU486
VEHICLE
SPIRO
RU486

Treatment
SALINE
SALINE
SALINE
KA
KA
KA
SALINE
SALINE
SALINE
KA
KA
KA

N
4
4
3
8
4
5
4
4
3
8
4
5

Mean LIVE neurons
per 100 um2
63.54 ± 3.06
62.46 ± 2.51
65.00 ± 2.25
60.79 ± 2.16
47.25 ± 14.81
48.90 ± 8.36
39.67 ± 1.69
34.63 ± 1.52
31.39 ± 6.54
30.38 ± 2.82
22.60 ± 3.92 a
28.10 ± 5.20

SPIRO = MR antagonist spironolactone
RU486 = GR antagonist mifepristone
KA = excitotoxin kainic acid
a
p ≤ 0.05 as compared to SPIRO/saline subjects (effect of kainic acid)
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Discussion
The present study characterizes the effects of MR and GR antagonists on plasma CORT
levels and hippocampal ACR mRNA regulation under basal conditions and after excitotoxic
challenge with kainic acid. We report increases in basal MR mRNA levels in CA1, CA3, and
DG following MR blockade and demonstrate increases in basal GR mRNA levels in CA3
following both MR and GR blockade. Further, we report that administration of the ionotropic
glutamate receptor agonist kainic acid reduces MR and GR mRNA levels in specific
hippocampal subfields at 24h following insult, indicating differential regulation of ACR mRNAs
during excitotoxic injury. Cell counts following KA administration provide evidence that the
magnitude of ACR mRNA downregulation exceeds that of cell loss.
Effects of ACR blockade and KA on CORT levels
In this study, pretreatment with SPIRO significantly increased basal CORT levels (Table
3.1). There is evidence that MR blockade with antagonist RU28318 increases CORT levels in
rat (Ratka et al., 1989; van Haarst et al., 1997), suggesting that the SPIRO-induced CORT
increase is due to MR blockade and a resultant disinhibition of adrenocortical secretion.
However, other studies using SPIRO have reported no significant effects on plasma CORT levels
(Chabert et al., 1984; Herman and Spencer, 1998). The reason for this disagreement may be
related to differing treatment protocols and durations.
Glucocorticoid receptor blockade with RU486 decreased basal CORT levels in this study.
This effect concurs with data demonstrating RU486-mediated suppression of CORT induction 15
minutes following introduction to a novel environment (Ratka et al., 1989). Considering the
relatively high CORT levels observed in our saline/vehicle-treated (control) subjects, the
observed decrease in CORT levels may reflect RU486-mediated reduction of CORT levels
subsequent to stress associated with either the euthanasia procedure or intraperitoneal injections
received the previous day. Despite its efficacy as a GR antagonist, RU486 can also act as a
partial GR agonist (Nordeen et al., 1995), which might explain a reduced stress response in
saline animals. However, CORT response to KA is not attenuated in RU486-treated animals,
suggesting that effects of RU486 on delayed negative feedback are minimal.
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Kainic acid induced a massive increase in CORT secretion observable 24h after injection.
Acute effects of KA include hyperactivity, “wet dog shakes”, and prolonged tonic-clonic
convulsions. Dehydration, brain edema, and perivenous hemorrhages are also common 24-48h
after KA injection (Sperk et al., 1983). It is therefore likely that the excitotoxin is a potent
stressor on multiple levels and thus increases CORT secretion for an extended period after
injection.
ACR antagonists modulate MR and GR mRNA levels
Treatment with the MR antagonist SPIRO increased basal MR mRNA levels in all observed
hippocampal subregions by approximately 30-40% (Figures 3.1 and 3.2).

These changes

complement reports of MR mRNA upregulation by adrenalectomy (Herman et al., 1989a; Reul
et al., 1989; Herman et al., 1993; Chao et al., 1998a) and provide additional evidence for
homologous feedback regulation of MR. The MR also appears to regulate expression of GR.
The present data demonstrate a significant SPIRO-induced increase in GR mRNA in CA3; GR
mRNA levels are similarly elevated in CA1 and DG of SPIRO-pretreated subjects but do not
reach our criteria for statistical significance. These data add to previous results from our
laboratory showing significant increases in GR mRNA levels in CA1 and DG with SPIRO
pretreatment (Herman and Spencer, 1998). In addition, the MR agonist aldosterone decreases
GR binding in primary hippocampal cell cultures (O'Donnell and Meaney, 1994), and
administration of aldosterone or low, MR-activating doses of CORT reverses ADX-induced
increases in GR mRNA (Chao et al., 1998a). Together, these results and the current data suggest
that MR functions as a tonic inhibitor of GR expression in hippocampus.
Preceding evidence also suggests that the activated glucocorticoid receptor negatively
regulates ACR expression. MR mRNA levels decrease during periods of high CORT secretion
(Herman et al., 1993) when the GR is most extensively activated (Reul and de Kloet, 1985).
Further, glucocorticoid receptor agonist dexamethasone reverses ADX-induced increases in GR
(Herman et al., 1989a; Reul et al., 1989) and MR (Herman et al., 1989a) mRNA levels and
reduces GR mRNA expression in culture (Rosewicz et al., 1988). In the present experiment,
RU486 significantly increased GR mRNA levels in CA3 (Figures 3.1 and 3.3), suggesting that
glucocorticoid receptor blockade increases GR biosynthesis by homologous feedback
mechanisms. However, RU486 did not increase MR mRNA levels, implying that glucocorticoid
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receptor regulation of MR is limited to suppressing MR levels during periods of extensive GR
activation.
SPIRO and RU486 are commonly used to achieve ACR blockade and are among the most
specific antagonists available, but like many other antagonist drugs they may produce some
nonspecific effects.

SPIRO is considered relatively specific for the MR but has been

demonstrated a weak GR antagonist in a transformed murine fibroblast cell line (Couette et al.,
1992). RU486 is an extremely potent GR antagonist in vitro, binding the GR with approximately
18 times the affinity of CORT, but also has strong anti-progestin activity (Baulieu, 1989).
RU486 may also act as a GR agonist under certain circumstances (Nordeen et al., 1995) and may
not be sufficient to fully block GR activation in vivo. However, it should be noted that the
currently reported antagonist effects correspond very well with the effects of adrenalectomy
(Herman et al., 1989a; Reul et al., 1989; Herman et al., 1993; Chao et al., 1998a); the antagonist
drugs increase hippocampal ACR mRNA expression in saline animals for the duration of the
experiment.
Excitotoxic challenge with KA decreases MR and GR mRNA levels
The present data show dramatic reductions in hippocampal MR and GR mRNA levels
following kainic acid insult (Figures 3.1, 3.2, and 3.3). KA-induced decreases in MR and GR
binding have previously been demonstrated using whole dissected hippocampus from
adrenalectomized rats (Lowy, 1992).

Reductions in MR and GR binding are similar in

magnitude to the currently reported mRNA decreases, are evident as early as one hour after
systemic KA administration, and persist for at least 24 hours (Lowy, 1992). Therefore, the
current data provide further evidence that MR and GR availability is reduced by KA and indicate
that this reduction is likely achieved through genomic downregulation, rather than by protein
degradation or receptor inactivation.
ACR downregulation by KA does not appear to be MR or GR-dependent. In the current
study, KA reduces ACR mRNA expression in the presence of MR or GR blockade. In addition,
a previous study has demonstrated that KA decreases ACR binding in adrenalectomized rats
(Lowy, 1992); corticosterone depletion in adrenalectomized rats prevents ACR activation and
their potential participation in the regulation of receptor expression. Furthermore, the pattern of
ACR downregulation produced by KA is inconsistent with the pattern of regulation associated
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with high CORT levels. High CORT levels decrease MR and GR mRNA levels by equal
proportions in CA1, CA3, and DG (Herman et al., 1993). In contrast, KA regulation of ACR
expression differs substantially by hippocampal subfield. Mineralocorticoid receptor expression
is downregulated in KA-sensitive regions CA1 and CA3, while GR expression is reduced in the
relatively KA-insensitive DG. These results suggest that KA regulation of ACR expression is
not mediated by KA induction of CORT, but that differential ACR regulation by KA is achieved
through other mechanisms related to KA susceptibility, such as glutamate receptor activation or
Ca2+ influx.
Interestingly, increases in MR and GR mRNA that occur with ACR antagonist pretreatment
are reversed by KA insult. Although KA does not affect MR mRNA levels in DG of vehiclepretreated animals, the SPIRO-induced increase in this region is negated by KA treatment.
Similarly, KA does not reduce GR mRNA levels in the pyramidal layers of vehicle-pretreated
animals, but SPIRO and RU486-induced increases in CA3 are abolished with KA injection.
These results suggest that homologous regulation of the receptors is suppressed or overridden by
KA, functionally disconnecting autoregulatory feedback.
Hippocampal pyramidal neurons are extremely sensitive to KA toxicity; CA3 neurons are
particularly vulnerable, while CA1 neurons are slightly less susceptible, to KA-induced damage
and cell degeneration (Nadler et al., 1978). The potential impact of cell loss on mRNA levels as
measured by in situ hybridization is an important consideration that is presently undetermined.
However, it is clear that in the hippocampal pyramidal layers, KA-induced decreases in MR
mRNA levels exceed the proportion of neuronal loss indicated by cell counts – by approximately
25 to 50% (see Figures 3.1, 3.2, and Table 3.2). Furthermore, DG granule cells are resistant to
KA toxicity and exhibit no histological damage after systemic KA administration (Sperk et al.,
1983). Therefore, the approximately 40-55% reduction in GR mRNA levels observed in DG is
not attributable to a decline in cell number.
KA-induced repression of ACR mRNA levels might influence neuronal viability during
injury. The receptors have potent cellular effects, some of which could endanger neurons under
compromising conditions.

For example, MR-modulated excitation of pyramidal neurons

(Reiheld et al., 1984; Joels and de Kloet, 1990, 1992) could be permissive to excitotoxic damage.
MR blockade with SPIRO has been shown to inhibit CORT-mediated increases in susceptibility
to KA-induced convulsions in mice (Roberts and Keith, 1994a, b). Thus, downregulation of the
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MR in pyramidal cells may reduce excitability and vulnerability to excitotoxic challenge.
Moreover, the GR has long been recognized as a potentially compromising influence on
hippocampal neurons. GR activation has been shown to increase intracellular calcium levels in
CA1 pyramidal cells (Kerr et al., 1992; Karst et al., 1994) and exacerbate the damaging effects of
toxic insults including KA, oxidative stress, and ischemia (Sapolsky, 1985; Sapolsky and
Pulsinelli, 1985; Sapolsky, 1986a; Sapolsky et al., 1988; Goodman et al., 1996; McIntosh and
Sapolsky, 1996a). Downregulation of the GR in dentate gyrus might protect granule cells from
effects of excitotoxicity such as extracellular glutamate accumulation, Ca2+ influx, and oxidative
stress.
MR blockade increases CA3 vulnerability to KA
Kainic acid decreased the number of live CA3 neurons counted in SPIRO-pretreated
subjects; however, KA had no significant effect on numbers of viable neurons in any other
region or group (Table 3.2). These data indicate that MR blockade increases susceptibility to
KA-induced degeneration in CA3. We have previously demonstrated that MR blockade with
SPIRO decreases basal mRNA levels of the anti-apoptotic gene bcl-2 in the hippocampal
pyramidal layers (McCullers and Herman, 1998) (Chapter Two). Thus, MR appears to play a
neuroprotective role during neuronal injury that may occur through maintenance of viabilityenhancing genes such as bcl-2.
The results of this study demonstrate that MR and GR mRNA levels respond to stress as
conveyed not only by differential receptor activation, but also by ACR-independent signals
generated by excitotoxic stress. Further, kainic acid regulation of ACR mRNA levels appears to
override ACR-dependent feedback mechanisms. The present evidence for modulation of ACR
mRNA expression during injury emphasizes the importance of ACR function for maintenance of
neuronal viability, particularly considering the prevalence of HPA dysregulation in
neurodegenerative conditions such as Alzheimer’s disease and in normal aging.
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Chapter Four: Mifepristone protects CA1 hippocampal neurons following
traumatic brain injury in rat
Introduction
Glucocorticoids modulate many cellular processes relevant to injury, including metabolism,
ion balance, immune function, inflammation, neurotrophin expression, and cell death (Munck et
al., 1984; McEwen et al., 1986; Reagan and McEwen, 1997; Joels and Vreugdenhil, 1998). Two
steroid hormone receptors mediate glucocorticoid action: the mineralocorticoid receptor (MR)
and the glucocorticoid receptor (GR). Glucocorticoids bind GR with lower affinity but higher
capacity relative to MR; thus, MR is extensively bound at very low (e.g. circadian nadir)
glucocorticoid levels, while GR mediates the effects of high glucocorticoid levels (Reul and de
Kloet, 1985; Reul et al., 1987). The MR and GR are abundantly expressed in hippocampus
(Reul and de Kloet, 1985; Aronsson et al., 1988; Arriza et al., 1988; Reul et al., 1989), making
this region a prime target for glucocorticoid action. Excessive activation of GR has been shown
to increase hippocampal neuronal vulnerability to several forms of neuronal insult, including
excitotoxicity, oxidative stress, and ischemia (Sapolsky, 1985; Sapolsky and Pulsinelli, 1985;
Sapolsky, 1986a; Sapolsky et al., 1988; Goodman et al., 1996; McIntosh and Sapolsky, 1996a).
Moderate to severe traumatic brain injury (TBI) in rat produces neuronal damage and cell
death in hippocampus (Cortez et al., 1989; Lowenstein et al., 1992; Goodman et al., 1994; Hicks
et al., 1996). The significant cell death that occurs following TBI is believed to evolve in a
biphasic sequence consisting of the primary mechanical insult coupled with a progressive
secondary necrosis.

Results of experimental TBI research have proposed several injury

mechanisms including excitotoxicity (Choi, 1992; Hayes et al., 1992), ischemia (Okiyama et al.,
1994), free radical formation (Braughler and Hall, 1992), elevated intracellular calcium (Young,
1992), edema (Wahl et al., 1988), proteolysis (Kampfl et al., 1997), and mitochondrial
dysfunction (Sullivan et al., 1998; Sullivan et al., 1999). Glucocorticoids likely modulate some
or all of the processes mediating secondary injury.

One possible mechanism whereby

glucocorticoids could influence neuronal vulnerability to injury is through regulation of the antiapoptotic B-cell leukemia/lymphoma-2 gene, bcl-2. Several studies indicate that bcl-2 is induced
by TBI and has neuroprotective effects after traumatic injury (Clark et al., 1997; Raghupathi et
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al., 1998; Nakamura et al., 1999). Our laboratory has demonstrated that MR blockade with
spironolactone decreases basal bcl-2 messenger RNA (mRNA) levels (McCullers and Herman,
1998) (Chapter Two), suggesting that MR activation maintains neuroprotective bcl-2 expression
and may participate in regulation of neuronal viability after TBI.
The present study is designed to test the hypotheses that GR blockade will attenuate and MR
blockade will exacerbate hippocampal cell loss following controlled cortical impact (CCI), an
experimental model of TBI.

Animals were pretreated with vehicle, the MR antagonist

spironolactone (SPIRO), or the GR antagonist mifepristone (RU486) and subsequently subjected
to either sham operation or injury by CCI. Using the optical fractionator method, CA1, CA3,
and dentate gyrus (DG) hippocampal neurons were counted twenty-four hours after surgery to
determine SPIRO and RU486 effects on cell survival after CCI. In addition, mRNA levels of the
anti-apoptotic gene bcl-2, the pro-apoptotic gene bax, and the tumor-suppressor gene p53 (a
transcriptional regulator of bcl-2 and bax) (Miyashita et al., 1994) were examined after MR or
GR blockade and CCI to determine whether MR or GR regulation of these genes correlates with
neuronal viability after traumatic brain injury.
Materials and Methods
Subjects
Young adult male Sprague Dawley rats (n=60) (Harlan Sprague Dawley, Inc., Indianapolis,
IN) weighing 200-250g were maintained on a 12 hr light/dark cycle in an environment with
constant temperature, humidity, and ad libitum access to food and water. All animal procedures
were performed in accordance with the National Institutes of Health guidelines and approved by
the University of Kentucky Institutional Animal Care and Use Committee. All efforts were
made to minimize animal suffering and the number of animals used.
In vivo protocols
Subjects received subcutaneous injections of propylene glycol vehicle, MR antagonist
spironolactone (SPIRO) (50 mg/kg) (Herman and Spencer, 1998) (Sigma, St. Louis, MO), or GR
antagonist RU486 (25 mg/kg) (Ratka et al., 1989) (Sigma) twice daily, in morning and afternoon.
Pretreatment was conducted for forty-eight hours to ensure adequate time for the altered
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expression of ACR-regulated genes (Herman and Spencer, 1998). After a final injection was
administered at 900h on day three, subjects were transported to a surgical procedure room.
Between 1100h-1200h, animals were subjected to craniotomy only (sham operation) or a
moderate unilateral cortical contusion (2mm). All animals were sacrificed on day four at 1200h,
approximately twenty-four hours after surgery.

8-12 subjects were included in each

pretreatment/surgery group. Half of the subjects in each condition were perfused for cell counts,
and half were decapitated for in situ hybridization analysis, yielding n = 4-6 subjects per
statistical group. Surgical procedures are briefly described below.
The moderate CCI injury used in these experiments results in significant loss of cortical
tissue, blood brain barrier disruption, and loss of hippocampal neurons as previously described
(Baldwin et al., 1997; Scheff and Sullivan, 1999), thus mimicking aspects of the pathology of
human closed-head injury. Animals were anesthetized with isoflurane (2%) and placed in a
stereotaxic frame (Kopf Instr., Tujunga, CA) prior to CCI injury. Using sterile procedures, the
skin was retracted and a 6mm unilateral craniotomy was centered between bregma and lambda.
The skull cap was removed without disruption of the underlying dura. The exposed brain was
injured using a pneumatically controlled impacting device with a 5mm beveled tip that
compressed the cortex 3.5 m/sec to a depth of 2mm. Following injury, Surgicel (Johnson and
Johnson, Arlington, TX) was laid upon the dura, and the skull cap was replaced. A thin coat of
dental acrylic was then spread over the craniotomy site and allowed to dry before the wound was
stapled closed. Body temperature was monitored continuously throughout the surgical/recovery
procedures and maintained at 37oC with a heating pad.
Animals processed for in situ hybridization experiments were killed by decapitation. Brains
were rapidly removed, frozen in isopentane cooled to –40oC on dry ice, then stored at –80oC
until sectioned. Trunk blood samples were collected on ice, and plasma was stored at -20 oC
until plasma corticosterone levels were measured using commercial radioimmunoassay kits per
manufacturers’ instructions (ICN Biochemicals, Costa Mesa, CA). Animals processed for cell
counts received a lethal dose of sodium pentobarbitol (Butler, Columbus, OH) (150mg/kg)
before undergoing transcardial perfusion with 0.9% saline followed by 4% paraformaldehyde.
Brains were removed and post-fixed in 4% paraformaldehyde overnight before further
processing.

57

Tissue processing
Frozen brains were removed from a –80oC freezer, warmed to –20oC, and sectioned to 16 um
with a Bright-Hacker cryostat. Sections were then thaw-mounted onto Ultrastick Slides (Becton
Dickinson, Franklin Lakes, NJ) and stored at –20oC until processing for in situ hybridization.
Perfused brains were processed as previously described (Baldwin et al., 1997). Briefly, brains
were placed in a graded series of celloidin (Mallinckrodt Baker, Inc., Paris. KY) dissolved in
50:50 ETOH:ethyl ether. After removal from 12% celloidin, the brains were placed in Peel-AWay (Polyscience, Warrington, PA) disposable histology embedding molds with fresh 12%
celloidin and exposed to chloroform vapors for 18 hours. Once the celloidin hardened, molds
were removed. The embedded tissue was then attached to wooden blocks and stored in 70%
EtOH until sectioning. The brains were cut in coronal sections (50 um) with a Zeiss HM440E
sliding microtome.

Sections were collected from anterior to posterior beginning at the

appearance of anterior hippocampus. In order to select a series in an unbiased manner such that
every section had an equal probability of being selected, a die was thrown to determine the first
section saved, after which every twelfth section was kept for staining with Giemsa. Six drops of
1% glacial acetic acid were added per 100 ml of Giemsa stain (Sigma, St. Louis, MO) diluted 1:4
with water. Following staining the sections were placed in cedar wood oil for 5 min to reduce
background and subsequently washed in Hemo-D (Fisher Scientific, Pittsburgh, PA).

The

sections were then mounted on slides, covered with permount, and coverslipped.
Optical fractionator method
Bioquant Image Analysis software (R and M Biometrics, Memphis, TN) was used to
estimate total cell number in regions of interest using the optical fractionator method of cell
counting. The optical fractionator method involves the combining of optical dissector counting
with fractionator sampling. This method of cell counting has several desirable attributes, such as
being unaffected by tissue shrinkage and not requiring rigorous definitions of structural
boundaries. For detailed explanation and discussion please see (West et al., 1991). The optical
fractionator involves counting neurons with optical dissectors in a uniform sample that
constitutes a known fraction of the structure being analyzed; the method systematically samples
a known fraction of the section thickness, of a known fraction of sectional area, of a known
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fraction of the sections that contain the region of interest. The equation is as follows (our
specific parameters):

N=

t

1

∑ Q • h • asf

•

1
ssf

Where N is the total number of neurons, and Σ Q is the total number of neurons counted in each
region of interest in each animal. t is the measured section thickness (42-45 um), h is the height
of the dissector (20 um), 1/asf is the counting grid area (100 um X 100 um)/ the dissector area
(20 um X 20 um), and 1/ssf is the sampling section fraction (12). Criteria for counting neuronal
nuclei were observed as previously described (Baldwin et al., 1997). Briefly, the plane of focus
was moved 5 um down from the top of the section to obviate the problem of an uneven counting
surface. Neuronal nuclei in focus at level –5 um, the top level of the dissector, were not counted,
but nuclei in focus at –25 um, the bottom level of the dissector, were counted. Through the
dissector, nuclei completely within the counting frame or touching the upper or right side of the
frame were counted. Nuclei touching the left or lower sides of the frame were not counted
(Baldwin et al., 1997).

Coefficient of error (CE) and coefficient of variation (CV) were

calculated to determine intra-animal variation and inter-animal variation, respectively (Tables 4.1
and 4.2).
Table 4.1. Mean coefficient of error (CE)
Vehicle
Spironolactone
RU486

CA1
0.082
0.090
0.071

CA3
0.144
0.143
0.122

Dentate gyrus
0.059
0.093
0.080

Table 4.2. Mean coefficient of variation (CV)
CA1
CA3
Dentate gyrus
Vehicle
0.241
0.365
0.156
Spironolactone
0.162
0.304
0.094
RU486
0.372
0.218
0.086
Cell count data were analyzed by two-way ANOVA within each subregion, with hemisphere
and drug designated as independent variables. Pairwise comparisons were made using the
Student-Neuman-Keuls test with significance set at p ≤ 0.05. Data in Figure 4.1 are presented as
neurons x 104 ± standard error.
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In situ hybridization
Antisense riboprobes complementary to coding regions for bcl-2 (550 bp) (courtesy of Dr. D.
Vaux, The Walter and Eliza Hall Institute, The Royal Melbourne Hospital, Victoria, Australia),
bax (100 bp) (courtesy of Dr. J. Springer, University of Kentucky, KY, USA), and p53 (950 bp)
(courtesy of Dr. G. Lozano, MD Anderson Cancer Center, Houston, TX, USA) mRNAs were
generated for in situ hybridization. Probes were labeled according to previously published
methods (Seroogy and Herman, 1996) by standard in vitro transcription using [35S]UTP. Tissue
sections removed from a –20oC freezer were fixed in 4% paraformaldehyde for 10 min. Slides
were then rinsed sequentially in the following solutions: 5 mM KPBS, 5 mM KPBS with 0.2%
glycine, 5mM KPBS, 0.1 M triethanolamine with 0.25% acetic anhydride, 0.2X SSC, and graded
alcohols. Labeled probes were added to a hybridization buffer containing 50% formamide, and
diluted probe (50 ul containing 1x 106 c.p.m.) was applied to each slide.
coverslipped, placed in moistened chambers, and incubated overnight at 55oC.

Slides were
Following

hybridization, slides were rinsed in 2X SSC and incubated in 0.2X SSC at 60oC for 1 hr. Slides
were then dehydrated and exposed for 14-18 days to Kodak BioMAX xray film.
Autoradiographic images were digitized with NIH Image 1.62 software for Macintosh. A
standard curve was generated prior to image capture to ensure linearity of the signal. Based on
morphological criteria, regions CA1, CA3, and DG of the hippocampal formation were manually
sampled from both hemispheres for densitometric analysis.

The mean gray level of an

unhybridized (background) area from each hemisphere was subtracted from sampled regions to
arrive at corrected gray level. Ipsilateral mRNA data were normalized as a percent of control
(sham/vehicle) values from the ipsilateral hemisphere, and contralateral mRNA data were
normalized as a percent of control (sham/vehicle) values from the contralateral hemisphere, with
sham/vehicle levels expressed as one hundred percent. In situ hybridization data were then
analyzed by two-way ANOVA within each hemisphere and subregion with drug and injury
designated as independent variables.

Post hoc comparisons were made using the Student-

Newman-Keuls test, with significance set at p ≤ 0.05.
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Results
Effects of adrenocorticosteroid receptor blockade and traumatic brain injury on hippocampal
neuron viability
The numbers of hippocampal neurons surviving CCI at 24 hours in hippocampal subregions
CA1, CA3, and DG were assessed using the optical fractionator method of cell counting (see
Methods). Because sham operation does not cause cell loss and damage is confined to the
ipsilateral hemisphere of injured rats, the numbers of neurons in sham/ipsilateral,
sham/contralateral, and injured/contralateral hemispheres were statistically indistinguishable (i.e.
unchanged by surgery) within each subregion (data not shown). Therefore, cell counts from
injured/contralateral hemispheres were used as control values against which to compare
injured/ipsilateral hemisphere values to determine the effects of CCI on neuronal survival.
Effects of antagonist pretreatments were assessed as compared to vehicle within the ipsilateral
and contralateral hemispheres.
Two-way ANOVA indicates a significant effect of hemisphere on numbers of neurons in
CA1 [F(1,24) = 9.32; p ≤ 0.05], CA3 [F(1,24) = 38.17; p ≤ 0.05], and DG [F(1,24) = 5.12; p ≤
0.05] (Figure 4.1). In CA1 of RU486-pretreated animals, numbers of surviving neurons were
statistically indistinguishable in the ipsilateral and contralateral hemispheres.

In contrast,

numbers of hippocampal neurons in CA1 of vehicle and SPIRO-pretreated animals were
significantly decreased by injury in the ipsilateral as compared to contralateral hemisphere. In
CA3, injury significantly reduced the number of viable pyramidal neurons in the ipsilateral
hemisphere in all pretreatment groups.

Injury also significantly decreased the number of

ipsilateral DG granule neurons counted in SPIRO and RU486-pretreated animals. Post-injury
corticosterone levels fell within the range of approximately 15-80 ng/ml in all drug pretreatment
groups, indicating that excessive corticosterone levels were not likely to contribute to the
differential neuronal survival between groups.
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Figure 4.1. Effects of MR blockade, GR blockade, and controlled cortical impact injury on
hippocampal neuron viability as measured by the optical fractionator method (see Methods).
Injury significantly decreased the number of viable neurons in CA1 and CA3 of vehiclepretreated animals (n = 6). Pretreatment with RU486 protected CA1 pyramidal neurons from
injury-induced cell loss (n = 5). Injury also decreased the number of viable neurons in CA3 and
dentate gyrus of spironolactone (n = 4) and RU486-pretreated animals. [B p ≤ 0.05 as compared
to contralateral hemisphere within same pretreatment group (effect of injury).]
Effects of adrenocorticosteroid receptor blockade and traumatic brain injury on bcl-2, bax, and
p53 mRNA levels
The effects of MR or GR blockade and CCI on hippocampal bcl-2, bax, and p53 mRNA
levels were determined using densitometric analysis following in situ hybridization with genespecific radiolabeled riboprobes (see Methods, Figure 4.2). Unlike measures of cell loss, mRNA
levels may be affected by injury both in the contralateral (unoperated) and ipsilateral (shamoperated or injured) hemispheres.

Therefore, all injury-induced changes were assessed as

compared to sham values from the same hemisphere. To this end, separate two-way ANOVAs
were conducted comparing sham/contralateral to injured/contralateral values and comparing
sham/ipsilateral to injured/ipsilateral values, with drug and injury as independent variables. In
each hemisphere, effects of drug were assessed as compared to vehicle within the sham or
injured treatment groups.
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Figure 4.2. Photomicrographs illustrating (A) bcl-2, (B) bax, and (C) p53 mRNA levels in
hippocampus of vehicle-pretreated, injured rats at 24h. Injury decreases bcl-2 mRNA levels in
ipsilateral dentate gyrus (panel A) but has no significant effect on bax or p53 mRNA levels in
vehicle-pretreated rats (panels B,C).
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Two-way ANOVA demonstrates significant drug/injury interaction effects on contralateral
bcl-2 mRNA levels in CA1 [F(2,27) = 3.47; p ≤ 0.05] and DG [F(2,27) = 5.67; p ≤ 0.05] (Figure
4.3). Post hoc comparisons indicate that bcl-2 signal was significantly decreased by RU486 and
by SPIRO in contralateral CA1 and DG of sham-operated animals. Injury increased contralateral
bcl-2 mRNA levels in DG of RU486 animals.
Drug/injury interaction effects on bcl-2 mRNA levels are observed in CA1 [F(2,27) = 5.01; p
≤ 0.05], CA3 [F(2,27) = 3.94; p ≤ 0.05], and DG [F(2,27) = 6.92; p ≤ 0.05] of the ipsilateral
hemisphere (Figure 4.3).

In sham-operated animals, ipsilateral bcl-2 mRNA levels were

significantly decreased by SPIRO in DG and by RU486 in CA1 and DG. CCI decreased
ipsilateral bcl-2 signal in DG of vehicle animals and increased ipsilateral bcl-2 signal in DG of
RU486 animals.
Overall, bax mRNA levels were increased in DG [F(1,28) = 4.49; p ≤ 0.05] (Figure 4.4)
contralateral to CCI. However, post hoc comparisons demonstrate no significant effects of drug
or injury on bax mRNA levels, in any region or hemisphere.
Significant effects of injury on p53 mRNA levels are detected in contralateral CA1 [F(1,29)
= 6.97; p ≤ 0.05] and DG [F(1,29) = 4.57] (Figure 4.5). Post hoc comparisons indicate that CCI
decreased contralateral p53 signal in CA1 and DG of SPIRO-pretreated animals. No significant
effects of drug or injury on p53 mRNA levels were observed in the ipsilateral hemisphere.
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Figure 4.3. Effects of MR blockade, GR blockade, and controlled cortical impact injury on bcl-2
mRNA levels in hippocampus. Semi-quantitative analysis expressed as percentage of control
(sham/vehicle; see methods) corrected gray level; n = 5-6 per group. Contralateral bcl-2 mRNA
levels were decreased by spironolactone and RU486 in CA1 and dentate gyrus of sham-operated
animals. Ipsilateral bcl-2 levels were decreased by spironolactone in dentate gyrus and by
RU486 in CA1 and dentate gyrus of sham-operated animals. Injury increased contralateral bcl-2
mRNA levels in dentate gyrus of RU486 animals. CCI decreased ipsilateral bcl-2 signal in
dentate gyrus of vehicle animals and increased ipsilateral bcl-2 signal in dentate gyrus of RU486
animals. [A p ≤ 0.05 as compared to vehicle animals within the same surgery condition (effect of
drug).

B

p ≤ 0.05 as compared to sham-operated animals within same drug pretreatment group

(effect of injury).]
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Figure 4.4. Effects of MR blockade, GR blockade, and controlled cortical impact injury on bax
mRNA levels in hippocampus. Semi-quantitative analysis expressed as percentage of control
(sham/vehicle; see methods) corrected gray level; n = 4-6 per group. Post hoc comparisons
indicate no significant effects of antagonist pretreatment or injury on bax mRNA levels in any
region or hemisphere.
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Figure 4.5. Effects of MR blockade, GR blockade, and controlled cortical impact injury on p53
mRNA levels in hippocampus. Semi-quantitative analysis expressed as percentage of control
(sham/vehicle; see methods) corrected gray level; n = 5-6 per group.

Injury decreased

contralateral p53 mRNA levels in CA1 and dentate gyrus of SPIRO-pretreated animals. Post hoc
comparisons indicate no significant effects of antagonist pretreatments. [B p ≤ 0.05 as compared
to sham-operated animals within same drug pretreatment group (effect of injury).]
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Discussion
The present study demonstrates that GR blockade with RU486 prevents CA1 neuron loss 24h
after CCI injury. The data do not suggest that regulation of viability-related genes bcl-2, bax, or
p53 is involved in the selective preservation of CA1 neurons by RU486. Furthermore, MR
blockade with SPIRO did not exacerbate CCI-induced neuron loss in hippocampus.
Hippocampal neuron loss 24 hours after controlled cortical impact injury
The present study uses the optical fractionator method of cell counting, a procedure that
yields an unbiased estimation of total cell number, to evaluate survival of hippocampal neurons
24h after CCI injury (Figure 4.1). Counts revealed that CCI significantly decreased the number
of ipsilateral CA1 pyramidal neurons in vehicle and SPIRO-pretreated rats by approximately
35%. In contrast, no significant cell loss occurred in RU486-pretreated animals, demonstrating
protection of CA1 neurons by RU486. Approximately 40-55% of CA3 neurons were lost at 24h.
We have previously reported a similar amount of cell loss in CA3 after the same level of injury
using the optical dissector method of cell counting. The same report demonstrated that no
significant cell loss occurs in CA3 beyond 24 hours post-injury, indicating that neuronal cell
death in this region is rapid following TBI (Baldwin et al., 1997). In the current study, CCI also
reduced the number of granule cells in DG by approximately 20-30%. While injury did not
significantly decrease the number of DG neurons in the vehicle-pretreated group, post-hoc
comparisons indicate that the amount of cell loss in vehicle-pretreated subjects was not
statistically different from that observed in SPIRO and RU486-pretreated subjects.

The

appearance of the data suggests that the actual extent of cell loss in vehicle-pretreated animals
may have been obscured by high variability in the number of contralateral cells counted in this
region.
RU486 protection is specific to CA1
The selective defense of CA1 neurons suggests either that RU486 preferentially protects this
neuronal population or that CCI injury in CA1 is more responsive to treatment. Differential
action of RU486 might be achieved through the heterogeneous distribution of GR across
subfields (Herman, 1993).

The high density of GR expressed in CA1 relative to other
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hippocampal regions might explain, in part, the efficacy of RU486. Relatively little GR is
expressed in CA3, perhaps lessening the impact of RU486 on this subregion. However, GR
levels are substantial in DG, a region not protected by RU486, suggesting that additional factors
are involved in determining neuronal susceptibility to injury.
Previous studies predict that CCI may affect neurons differently according to subregion,
allowing for selective intervention. Subpopulations of hippocampal neurons are selectively
vulnerable to different forms of insult; CA1 neurons are most severely damaged by ischemia
(Kirino, 1982; Pulsinelli et al., 1982; Schmidt-Kastner and Freund, 1991), while CA3 neurons
are most vulnerable, and DG granule cells least vulnerable, to kainate excitotoxicity (Nadler et
al., 1978; Kohler and Schwarcz, 1983). Ischemia (Okiyama et al., 1994) and excitotoxicity
(Choi, 1992; Hayes et al., 1992) are among the many components of TBI which can lead to
neuronal death. Differential vulnerability in hippocampal neuron populations could therefore
govern the severity of CCI injury or the length of time over which cell death occurs, allowing for
more successful treatment in specific regions. CCI results in very rapid cell loss in CA3
(Baldwin et al., 1997). Death of CA1 neurons as induced by ischemia is slower in comparison,
occuring over a period of hours to days (Kirino, 1982; Pulsinelli et al., 1982). It is possible that
CCI injury is either delayed or less severe in CA1 as compared to CA3, such that intervention
with RU486 is able to increase or prolong neuronal survival. Clarification of this issue will
require further elucidation of the mechanisms governing CCI-induced cell death and a time
course characterization of CA1 neuron survival after CCI.
A variety of factors could account for differential vulnerability to TBI by region. For
example, CA3 neurons do not express neuronal calcium-binding proteins calbindin-D28k or
parvalbumin (Sloviter, 1989), which may reduce CA3 Ca2+ buffering capacity as compared to
CA1.

In addition, ionotropic glutamate receptors are heterogeneously distributed in

hippocampus; NMDA and AMPA subunits are preferentially expressed in CA1 and DG, while
kainate receptors are mainly found in CA3 (Greenamyre et al., 1985; Tarazi et al., 1996).
Glutamate receptor configuration may dictate sensitivity to the large amounts of glutamate
released during injury. Subregional differences in afferent input, intracellular signaling, control
of ion homeostasis, antioxidant defenses, and neurotrophic factor expression are among other
factors that could also differentially influence cell viability.
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Glucocorticoid receptor blockade and neuronal viability
GR-activating concentrations of glucocorticoids exacerbate many types of neuronal insult
including kainic acid toxicity, oxidative stress, amyloid-beta peptide toxicity, and ischemia
(Sapolsky, 1985; Sapolsky and Pulsinelli, 1985; Sapolsky, 1986a; Sapolsky et al., 1988;
Goodman et al., 1996; McIntosh and Sapolsky, 1996a).

The GR may heighten neuronal

sensitivity to insult through several mechanisms. Glucocorticoids can inhibit glucose transport
(Horner et al., 1990) and may increase neuronal vulnerability to insult through energy depletion
(Sapolsky, 1986b). Elevated glucocorticoid concentrations can also result in excitatory amino
acid accumulation (Stein-Behrens et al., 1992; Stein-Behrens et al., 1994b), increased
intracellular Ca2+ concentrations (Kerr et al., 1992; Elliott and Sapolsky, 1993; Karst et al.,
1994), and free radical formation (McIntosh and Sapolsky, 1996a, b), all of which may
compromise cells by triggering Ca2+-dependent proteolysis, lipid peroxidation, oxidative stress,
and mitochondrial dysfunction.
Inactivation of GR by glucocorticoid removal or GR blockade has been shown to improve
survival of rodent hippocampal neurons following several types of neurotoxic challenge.
Metyrapone, an inhibitor of adrenal glucocorticoid synthesis, reduces loss of CA1 neurons after
ischemia (Smith-Swintosky et al., 1996) and loss of CA1 and CA3 neurons after insult with
kainic acid, an excitotoxic glutamate analog (Stein and Sapolsky, 1988; Smith-Swintosky et al.,
1996). RU486 reverses glucocorticoid-mediated vulnerability to glutamate in a cultured murine
hippocampal cell line (Behl et al., 1997b). Further, RU486 (Antonawich et al., 1999) and
removal of endogenous glucocorticoids by adrenalectomy (Sapolsky and Pulsinelli, 1985; Morse
and Davis, 1990) attenuate loss of CA1 neurons following ischemia. However, studies have
indicated that while adrenalectomy and RU486 improve CA1 viability in gerbil at 4 days
following ischemia, the protection is lost at 7 days (Morse and Davis, 1990; Antonawich et al.,
1999). Thus it is possible that RU486 protection of CA1 neurons after CCI is a transient effect.
Additional time points will be required in order to determine if RU486 completely prevents CA1
cell loss or merely delays neuronal loss after injury.
Metyrapone and adrenalectomy studies suggest that RU486 may exert its neuroprotective
effects by blocking the deleterious effects of GR. RU486 is a potent inhibitor of GR activation
that both impedes and competes with glucocorticoid binding to the GR. Complexes of RU486
bound to the GR can bind glucocorticoid response elements found in target gene promoter
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regions but do not facilitate transcription, c.f.(Cadepond et al., 1997). While RU486 generally
acts as an anti-glucocorticoid, it may also act as a GR agonist under certain circumstances
(Nordeen et al., 1995). It is therefore possible that RU486 influences GR activation in an
unpredicted manner after CCI. However, we have consistently observed in the current subjects
(McCullers, 2001a) (Chapter Five) and in a previous study (McCullers and Herman, 2001)
(Chapter Three) that in vivo pretreatment with RU486 increases GR mRNA levels. This effect
concurs with GR mRNA upregulation after adrenalectomy (Herman et al., 1989a; Reul et al.,
1989) and provides evidence for the functional blockade of GR in this study. In addition to its
anti-glucocorticoid effects, RU486 is also a potent progesterone receptor antagonist. However,
modest hippocampal expression of progesterone receptor (Kato et al., 1994) and evidence that
progesterone is neuroprotective after TBI (Roof and Hall, 2000) suggest that progesterone
receptor blockade is unlikely to underlie RU486 protection of CA1 neurons after CCI.
Potential mechanisms of RU486 neuroprotection
Subfield-specific modulation of Ca2+ homeostasis may influence neuronal viability after TBI.
Studies of CA1 neurons in hippocampal slices demonstrate enhanced afterhyperpolarization
(Joels and de Kloet, 1989; Kerr et al., 1989), Ca2+ action potentials (Kerr et al., 1989), and Ca2+
currents (Kerr et al., 1992; Karst et al., 1994) with increased GR activation. These reports
indicate that GR influences Ca2+ influx in CA1 neurons and suggest that excessive GR activation
could lead to Ca2+ neurotoxicity. In agreement with this hypothesis, prolonged exposure to high
glucocorticoid concentrations increases basal intracellular Ca2+ levels (Elliott and Sapolsky,
1993) and prolongs intracellular Ca2+ elevation after kainic acid treatment (Elliott and Sapolsky,
1992) in hippocampal neuron cultures.

Characterizations of Ca2+ channel subunit mRNA

expression at low and high glucocorticoid levels are also consistent with the hypothesis that
predominant MR occupation leads to restricted Ca2+ influx, while additional GR occupation
enhances Ca2+ influx (Nair et al., 1998). In the present study, RU486 blockade of GR should
result in predominant MR activation. RU486 may therefore shift expression of Ca2+ channel
subunits and other Ca2+ regulatory genes to a neuroprotective configuration that could prevent
excessive intracellular Ca2+ accumulation in CA1 neurons.
RU486 could also improve CA1 neuronal viability via non-genomic action. RU486 is
reported to have antioxidant effects that may mediate neuroprotection in CA1 pyramidal cells.
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Previous studies have shown that RU486 prevents oxidation of the low-density lipoprotein
(Parthasarathy et al., 1994) and inhibits oxidative modification of proteins by pre-existing lipid
peroxides in cell-free systems (Carpenter et al., 1996). Furthermore, Behl, et al. (1997a) have
demonstrated neuroprotective antioxidant effects of RU486 in cellular and organotypic slice
cultures. Pretreatment with 10-5 M RU486 protects rat primary hippocampal cultures from beta
amyloid toxicity, mouse clonal hippocampal HT22 cells from beta amyloid, H2O2, and glutamate
insults, and organotypic rat hippocampal slices from H2O2-induced cell death (Behl et al.,
1997a). Intracellular peroxide accumulation and DNA degradation were also prevented by
RU486 in HT22 cells. Experiments in monkey kidney CV1 cells suggest that the protective
effects of RU486 are independent of GR or PR antagonism or activation (Behl et al., 1997a).
Structural similarity to other antioxidant compounds suggests that the dimethylaminophenyl side
chain moiety of RU486 is likely responsible for the antioxidant properties of RU486
(Parthasarathy et al., 1994; Carpenter et al., 1996; Behl et al., 1997a).
Expression of apoptosis-related genes after corticosteroid receptor blockade and injury
The present data demonstrate decreased hippocampal bcl-2 mRNA levels in SPIRO and
RU486-pretreated rats 24h after sham-operation, as compared to vehicle-pretreated subjects
(Figure 4.3). These results extend our previous finding that SPIRO decreases bcl-2 mRNA
levels in hippocampus (McCullers and Herman, 1998) (Chapter Two).

This evidence for

reduction of bcl-2 mRNA levels by MR and GR antagonists suggests that both receptor types,
perhaps functioning as heterodimers (Trapp et al., 1994), are required for optimal maintenance of
bcl-2 expression. However, the antagonist-induced decreases in bcl-2 mRNA levels observed in
sham animals do not appear to predict increased hippocampal neuron vulnerability to injury.
Injury-induced cell loss is not increased in antagonist-injected subjects in any region (as
compared to vehicle-injected controls); on the contrary, RU486 treated subjects clearly show
protection despite decreased bcl-2 mRNA levels observed in sham animals. These data fail to
support the hypothesis that decreased bcl-2 expression subsequent to ACR blockade will increase
neuronal vulnerability to CCI. It should be noted, however, that the effects of ACR blockade on
bcl-2 mRNA levels are very different in sham versus injured animals. Among injured animals,
ACR blockade did not reduce bcl-2 mRNA levels (as compared to vehicle-injected controls) 24
hours post-injury in any hippocampal region.
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Thus, CCI injury abrogates the differential

decrease of bcl-2 mRNA levels in antagonist-pretreated groups, perhaps accounting for the lack
of correlation between sham bcl-2 levels and injury induced cell loss. Nonetheless, it is possible
that a shorter period of antagonist pretreatment may be sufficient for RU486 protection of CA1
neurons while avoiding the potential undesired effect of bcl-2 mRNA downregulation.
The present study demonstrates decreased ipsilateral bcl-2 mRNA levels in DG of vehiclepretreated subjects following CCI injury.

Decreased bcl-2 expression has also been

demonstrated in fluid percussion (Dong et al., 2001) and in vitro (Morrison et al., 2000) models
of TBI. In contrast, Clark et al. have reported increases in hippocampal bcl-2 mRNA levels 24h
following CCI with the addition of 30 minutes moderate hypoxemia following injury (Clark et
al., 1997). Increased bcl-2 mRNA levels appear to be associated with neuroprotection after CCI
with hypoxia (Clark et al., 1997), and Bcl-2 overexpression in transgenic mice decreases
hippocampal tissue loss after CCI (Nakamura et al., 1999). In addition, decreased bcl-2 mRNA
levels have been associated with increased kainate-induced hippocampal cell loss (Gillardon et
al., 1995; McCullers and Herman, 2001) (Chapter Three). However, decreased bcl-2 mRNA
levels observed in DG of injured animals in the current study were not associated with
significant neuronal loss following CCI injury. As previously noted, a high degree of variability
in contralateral DG cell counts may have obscured significant effects of CCI on DG neuron loss.
Even so, the process of secondary neuronal degeneration is very complex and involves numerous
factors, and decreased bcl-2 expression, though perhaps an endangering factor, need not dictate
neuronal loss following injury.
Hippocampal bax mRNA levels were unchanged by MR/GR antagonist pretreatments or CCI
(Figure 4.4).

These findings agree with results obtained using an in vitro model of TBI

(Morrison et al., 2000). The ratio of anti-apoptotic proteins such as Bcl-2 to pro-apoptotic
proteins such as Bax is believed to determine cell sensitivity to apoptotic signals (Oltvai et al.,
1993).

The current data suggest that transcriptional regulation of this ratio would be

accomplished by modulation of bcl-2, and not bax, following traumatic brain injury.
Levels of p53 mRNA in the present study were not significantly elevated in vehiclepretreated animals at the 24 hour time point; however, our data do not preclude changes earlier in
time. For instance, another group has demonstrated increases in p53 mRNA levels 6 hours
following fluid percussion brain injury which return to sham levels by 24 hours (Napieralski et
al., 1999). The current report also demonstrates that injury reduced contralateral p53 signal in
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CA1 and DG of SPIRO animals (Figure 4.5). We have previously shown that SPIRO attenuates
kainic acid-induced increases in p53 mRNA levels (McCullers and Herman, 1998) (Chapter
Two), but the effects of p53 downregulation on neuronal survival are presently unclear.
Hippocampal cell death is associated with functional (Lowenstein et al., 1992) and
neurobehavioral (Hicks et al., 1993; Smith et al., 1994) deficits following TBI. By preventing
CA1 neuron loss after CCI, RU486 could potentially improve behavioral outcome after injury.
RU486 may be particularly effective in promoting neuron survival due to its combined antiglucocorticoid effects and antioxidant properties.

While glucocorticoids have been used

clinically to control edema after TBI, the value of this treatment is unclear. Some evidence
indicates that glucocorticoids can improve recovery after central nervous system injury (Hall et
al., 1992), but many studies show no improvement with glucocorticoid administration (Tornheim
and McLaurin, 1978; Cooper et al., 1979; Giannotta et al., 1984; Brain, 1996). In contrast, many
studies have demonstrated exacerbation of neuronal insult by glucocorticoids (Sapolsky, 1985;
Sapolsky and Pulsinelli, 1985; Sapolsky, 1986a; Sapolsky et al., 1988; Goodman et al., 1996;
McIntosh and Sapolsky, 1996a) and improved neuronal viability with antiglucocorticoid
treatments (Sapolsky and Pulsinelli, 1985; Stein and Sapolsky, 1988; Morse and Davis, 1990;
Smith-Swintosky et al., 1996; Behl et al., 1997b; Antonawich et al., 1999). Considering the
benefits of glucocorticoid removal and blockade in other models of neuronal injury, the
antioxidant properties of RU486, and the current data demonstrating CA1 neuron protection,
RU486 appears to have potential as a useful treatment for head injury.

74

Chapter Five: Traumatic brain injury regulates adrenocorticosteroid
receptor mRNA levels in rat hippocampus
Introduction
The mineralocorticoid receptor (MR) and the glucocorticoid receptor (GR), collectively
referred to as adrenocorticosteroid receptors (ACRs), are ligand-activated transcription factors
that mediate glucocorticoid action in brain. The MR binds glucocorticoids with high affinity (kD
~ 0.5-1 nM) and is extensively occupied at basal glucocorticoid levels (Reul and de Kloet, 1985).
The GR binds glucocorticoids with a five-fold lower affinity, resulting in greater GR activation
with increasing glucocorticoid levels (i.e. during stress and at the peak of circadian hormone
secretion)(Reul and de Kloet, 1985; Spencer et al., 1990). This two-receptor system allows for
differential regulation of MR and GR-coordinated gene expression in response to changes in
circulating glucocorticoid concentration. The binding of glucocorticoid ligand allows receptor
translocation to the cell nucleus, where the MR and GR can regulate transcription either by direct
DNA binding to hormone response elements in gene promoter regions or by protein-protein
interactions with other transcription factors [see (Yamamoto, 1985; De Kloet et al., 1998)].
Considerable evidence suggests that excessive GR activation by CORT increases
hippocampal vulnerability to several forms of neuronal insult including excitotoxicity, oxidative
stress, and ischemia (Sapolsky, 1985; Sapolsky and Pulsinelli, 1985; Sapolsky, 1986a; Sapolsky
et al., 1988; Goodman et al., 1996; McIntosh and Sapolsky, 1996a). Furthermore, blockade of
GR reduces hippocampal neuron vulnerability to traumatic brain injury (TBI) (McCullers et al.,
2001b) (Chapter Four), indicating the potential deleterious effects of GR activation with this type
of injury. The degree of GR activation experienced by cells is largely determined by circulating
glucocorticoid concentration and the amount of available GR; therefore, regulation of GR
expression and the magnitude of HPA response are crucial determinants of glucocorticoid
influence on neuronal viability after injury.
To examine the respective roles of MR and GR in regulating ACR expression and
glucocorticoid secretion following TBI, adult male Sprague Dawley rats were pretreated with
vehicle, the MR antagonist spironolactone (SPIRO), or the GR antagonist mifepristone (RU486).
Subjects were subsequently sham-operated or injured using the controlled cortical impact (CCI)
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model of TBI. Twenty-four hours post-injury, ACR mRNA levels were measured to determine
if glucocorticoid signaling is altered through regulation of ACR expression following injury. As
the acute hypothalamic-pituitary-adrenal (HPA) response to CCI has not been characterized,
additional studies were performed to assess CORT and ACTH secretion over the 24-hour period
following injury.
Materials and Methods
Subjects
Young adult male Sprague Dawley rats (Harlan Sprague Dawley, Inc., Indianapolis, IN)
weighing 200-250g were maintained in an environment with constant temperature, humidity, ad
libitum access to food and water, and a 12-hour light/dark cycle, with lights on between 600h1800h. All measures were taken to minimize animal pain or discomfort. All animal procedures
were performed in accordance with the National Institutes of Health guidelines and approved by
the University of Kentucky Institutional Animal Care and Use Committee.
In vivo protocols
Subjects (n = 5-7 per design group) received subcutaneous injections of propylene glycol
vehicle, MR antagonist spironolactone (SPIRO) (50 mg/kg) (Herman and Spencer, 1998)
(Sigma, St. Louis, MO), or GR antagonist RU486 (25 mg/kg) (Ratka et al., 1989) (Sigma) in
morning (900h) and afternoon (1600h) for two days. On day three, animals were administered a
final pretreatment injection at 900h and transported to a surgical procedure room. Between
1100h-1200h, animals were subjected to craniotomy (sham operation) or a moderate unilateral
cortical contusion, described below. Subjects were killed on day 4 at 1200h, 24h after surgery.
A separate set of animals (n = 6 per group) was used for analysis of plasma ACTH and
CORT levels during the 24 hours following surgery. Baseline blood samples were drawn by tail
nick between 900-1000 hours, after which animals were transported to a surgical procedure
room.

Subjects then underwent sham operation or moderate unilateral cortical contusion

between 1200-1300 hours. Sham and CCI surgeries were performed under identical conditions
on separate days. Blood samples were collected at 1.5, 6, 12, 18, and 24 hours after the start of
surgery. All samples were collected by tail nick, with the exception of the 24-hour point, which
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was obtained by collection of trunk blood at the time of sacrifice. Blood sampling was initiated
1.5 hours after the start of surgery to allow all subjects to wake from anesthesia, and six hour
intervals were observed thereafter to assess circadian hormone levels at times including lights off
(1800 h) and lights on (600h).
Surgical procedures were performed as previously described (Baldwin et al., 1997). Briefly,
animals were anesthetized with isoflurane (2%) and placed in a stereotaxic frame (Kopf Instr.,
Tujunga, CA). Sterile procedures were used to retract the skin and perform a 6mm unilateral
craniotomy midway between bregma and lambda. The underlying dura was not disrupted during
removal of the portion of skull. A pneumatically controlled impacting device with a 5mm
beveled tip was used to injure the exposed brain, compressing the cortex at 3.5m/sec to a depth
of 2mm. Following injury, Surgicel (Johnson and Johnson, Arlington, TX) was laid upon the
dura, and the skull cap was replaced. After a thin coat of dental acrylic was spread over the
craniotomy site and allowed to dry, the wound was stapled closed. Body temperature was
monitored continuously throughout the surgical/recovery procedures and maintained at 37oC
with a heating pad.
Animals processed for these experiments were killed by decapitation. Brains were rapidly
removed, frozen in isopentane cooled to –40oC on dry ice, then stored at –80oC until sectioned.
Trunk blood samples were collected on ice, and plasma was stored at –20 oC. Frozen brains were
removed from a –80oC freezer, warmed to –20oC, and sectioned to 16 um with a Bright-Hacker
cryostat. Sections were then thaw-mounted onto Ultrastick Slides (Becton Dickinson, Franklin
Lakes, NJ) and stored at –20oC until processing for in situ hybridization.
In situ hybridization
Antisense riboprobes complementary to coding and 3’ untranslated regions for rat MR
mRNA (550 bp, courtesy of P. Patel and S. Watson, Univ. Michigan) and rat GR mRNA (456
bp, courtesy of K. Yamamoto, UCSF) were labeled according to previously published methods
(Seroogy and Herman, 1996) by standard in vitro transcription using [35S]UTP. Slide-mounted
tissue sections were removed from a -20oC freezer and fixed in 4% paraformaldehyde for 10
min. Slides were then rinsed in 5 mM KPBS, 5 mM KPBS with 0.2% glycine, 5mM KPBS, 0.1
M triethanolamine with 0.25% acetic anhydride, and 0.2X SSC, then dehydrated in graded
alcohols. Labeled probes were diluted in hybridization buffer containing 50% formamide, and
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50 ul of diluted probe (containing 1x 106 c.p.m.) was applied to each slide. Slides were then
coverslipped, placed in moistened chambers, and incubated overnight at 55oC.

Following

hybridization, slides were rinsed in 2X SSC and incubated in 0.2X SSC at 60oC for 1 hr. After
dehydration in graded alcohols, slides were exposed for 14-18 days to Kodak BioMAX xray
film.
Densitometric analysis was performed using NIH Image 1.62 software for Macintosh. A
standard curve was generated using

14

C standards prior to image capture to ensure signal

linearity. Based on morphological criteria, regions CA1, CA3, and DG of the hippocampal
formation were manually sampled from the ipsilateral (operated) and contralateral (unoperated)
hemispheres. The mean gray level of an unhybridized area (background) from each hemisphere
was subtracted from sampled regions to compute corrected gray level. Ipsilateral mRNA data
were normalized as a percent of control (sham/vehicle) values from the ipsilateral hemisphere,
and contralateral mRNA data were normalized as a percent of control (sham/vehicle) values
from the contralateral hemisphere, with sham/vehicle levels expressed as one hundred percent.
Each region of each hemisphere was then analyzed by two-way analysis of variance with drug
and injury designated as independent variables. Post hoc comparisons were made using the
Student-Newman-Keuls test, with significance set at p ≤ 0.05.
Radioimmunoassay
Plasma ACTH and corticosterone concentrations were determined using (125I-labeled) rat
ACTH (Diasorin, Stillwater, MN, USA) and corticosterone (ICN Biochemicals, Costa Mesa,
CA) kits per manufacturers’ instructions. The limits of detection for each kit are 15 pg/ml and 8
ng/ml, respectively.
A skewed distribution of CORT levels observed in subjects pretreated with antagonist drugs
was normalized by log transformation of the data prior to analysis for significant main effects by
two-way analysis of variance. Post hoc comparisons were made using the Student-NewmanKeuls test, with significance set at p ≤ 0.05. Data presented in Table 5.1 are actual CORT values
listed as mean concentration ± standard error. Time course values for ACTH and CORT were
analyzed for significant main effects using a repeated measures analysis of variance. Post hoc
comparisons were made using the Student-Newman-Keuls test, with significance set at p ≤ 0.05.
Data graphed in Figures 5.1 and 5.2 represent mean hormone concentration ± standard error.
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Results
Effects of ACR blockade and CCI on plasma ACTH and corticosterone levels
ACTH and CORT levels were measured 24 hours following surgery to assess the effects of
ACR blockade and CCI on HPA activation. Two-way ANOVA demonstrates a significant
drug/injury interaction effect on plasma CORT levels at 24h [F(2,29) = 8.02; p ≤ 0.05] (Table
5.1). Post hoc comparisons indicate that SPIRO significantly increased CORT secretion in
sham-operated animals.

Controlled cortical impact significantly decreased CORT levels in

SPIRO and RU486-pretreated animals as compared to sham-operated animals within the same
drug pretreatment groups. RU486 animals also had significantly lower CORT levels after injury
as compared to vehicle/injured animals.
Table 5.1. Effects of adrenocorticosteroid receptor blockade and controlled cortical impact on
plasma corticosterone levels (ng/ml)
Group
Treatment
VEHICLE
SHAM
SPIRO
SHAM
RU486
SHAM
VEHICLE INJURED
SPIRO INJURED
RU486 INJURED

n
7
6
6
5
6
5

Mean CORT Level
80.5 ± 29.9
324.5 ± 77.2 a
121.0 ± 16.2
81.7 ± 33.6
51.9 ± 26.0 b
14.7 ± 6.8 a,b

SPIRO = MR antagonist spironolactone
RU486 = GR antagonist (mifepristone)
a
p < 0.05 compared to vehicle-pretreated subjects in same surgery group (effect of antagonist)
b
p < 0.05 compared to sham-operated subjects in same pretreatment group (effect of injury)
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Plasma ACTH and corticosterone levels: time course after injury
Blood samples taken 24 hours after surgery suggest the dynamic regulation of CORT
secretion over the post-injury period. To examine the kinetics of HPA activation following CCI,
additional animals were subjected to sham operation or injury, after which sequential blood
samples were drawn by tail nick over the 24-hour post-surgery period. Plasma ACTH levels
exhibited a significant injury/time interaction as determined by repeated measures analysis of
variance [F(5,41) = 7.89; p ≤ 0.05] (Figure 5.1). Plasma ACTH concentrations were increased to
approximately 200 pg/ml at 1.5 hours and at 18 hours post-surgery in injured animals. ACTH
concentrations in sham-operated animals were indistinguishable from baseline at all time points.
Plasma CORT concentrations also demonstrate a significant injury/time interaction as
indicated by repeated measures analysis of variance [F(5,50) = 5.29; p ≤ 0.05] (Figure 5.2).
Corticosterone levels are significantly increased in injured rats at 1.5 hours (109 ± 12 ng/ml) and
at 6 hours (53 ± 4 ng/ml) following surgery, but returned to baseline by 12 hours and remained
unchanged for the rest of the 24-hour period. Corticosterone concentrations in sham-operated
animals were indistinguishable from baseline at all time points.
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Figure 5.1. Twenty-four hour time course analysis of plasma ACTH levels (pg/ml) following
controlled cortical impact. Injury increased ACTH levels at 1.5 and 18 hours after surgery (p ≤
0.05). ACTH levels in sham-operated animals were indistinguishable from baseline at all time
points.

Figure 5.2. Twenty-four hour time course analysis of plasma corticosterone levels (ng/ml)
following controlled cortical impact. Injury increased corticosterone secretion at 1.5 and 6 hours
after surgery (p ≤ 0.05); levels returned to baseline by 12 hours after injury. Corticosterone
levels in sham-operated animals were indistinguishable from baseline at all time points.
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Effects of ACR blockade and CCI on ACR mRNA levels
Relative changes in mRNA levels were measured by film densitometry following in situ
hybridization with specific complementary antisense riboprobes (see Methods) (Figure 5.3).

Figure 5.3. Photomicrographs illustrating the effects of sham operation (A,C) and controlled
cortical impact (B,D) on MR (A,B) and GR (C,D) mRNA levels in hippocampus of vehiclepretreated rats. Panels A,B: Controlled cortical impact has no significant effects on MR mRNA
levels in vehicle-pretreated animals. Panels C,D: Controlled cortical impact decreases ipsilateral
GR mRNA levels in dentate gyrus and increases contralateral GR mRNA levels in CA1 and DG
of vehicle-pretreated subjects.
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In the hemisphere contralateral to injury, two-way ANOVA demonstrates significant main
effects of injury on MR mRNA levels in CA1 [F(1,28) = 13.10; p ≤ 0.05], CA3 [F(1,28) = 32.39;
p ≤ 0.05], and DG [F(1,28) = 4.31; p ≤ 0.05] (Figure 5.4). Post hoc comparisons indicate that
injury induces significant contralateral increases in MR mRNA levels in CA1 of SPIROpretreated animals and in CA3 of SPIRO and RU486 animals; comparisons in DG did not reach
statistical significance.

No significant effects of antagonist pretreatment were observed in

contralateral MR mRNA levels.
In the injured hemisphere, two-way ANOVA demonstrates significant main effects of injury
on MR mRNA levels in CA1 [F(1,28) = 6.55; p ≤ 0.05] and CA3 [F(1,28) = 42.18; p ≤ 0.05]
(Figure 5.4).

Post hoc comparisons indicate that cortical impact significantly increased

ipsilateral MR mRNA levels in CA1 of RU486-pretreated animals and in CA3 of SPIRO and
RU486 animals. A significant main effect of drug on MR mRNA levels is observed in ipsilateral
CA1 [F(2,28) = 3.68; p ≤ 0.05], but post hoc comparisons did not distinguish between individual
pretreatment groups.
Contralateral GR mRNA levels exhibited significant drug/injury interactions in CA1 [F(2,28)
= 7.75; p ≤ 0.05] and DG [F(2,28) = 5.70; p ≤ 0.05] (Figure 5.5). In sham-operated animals,
SPIRO and RU486 increased contralateral GR signal in CA1 and DG. Cortical injury increased
contralateral GR mRNA levels in CA1 and DG of vehicle-pretreated animals and decreased
contralateral GR mRNA levels in CA1 of RU486 animals.
Main effects of drug/injury interaction were observed in ipsilateral GR mRNA levels in
subregions CA1 [F(2,28) = 6.53; p ≤ 0.05], CA3 [F(2,28) = 3.71; p ≤ 0.05], and DG [F(2,28) =
4.29; p ≤ 0.05] (Figure 5.5). RU486 significantly increased ipsilateral GR signal in CA1, CA3,
and DG of sham-operated animals, and SPIRO increased ipsilateral GR signal in CA1. Cortical
impact significantly decreased ipsilateral GR mRNA levels in CA1 and CA3 of SPIRO and
RU486-pretreated animals and in DG of all antagonist pretreatment groups.
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Figure 5.4. Effects of MR blockade (SPIRO), GR blockade (RU486), and controlled cortical
impact (CCI) injury on MR mRNA levels in hippocampus. Semi-quantitative analysis expressed
as percentage of control (sham/vehicle) corrected gray level. Injury and antagonist pretreatments
interact to increase contralateral and ipsilateral MR mRNA levels in CA1 and CA3. [B p ≤ 0.05
as compared to sham-operated animals within same pretreatment group (effect of CCI).]
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Figure 5.5. Effects of MR blockade, GR blockade, and controlled cortical impact (CCI) injury
on GR mRNA levels in hippocampus. Semi-quantitative analysis expressed as percentage of
control (sham/vehicle) corrected gray level. Antagonist pretreatment increases GR mRNA levels
in sham-operated animals, but antagonist-induced increases in GR mRNA levels are prevented
by injury. Contralateral GR mRNA levels are increased in CA1 and DG of vehicle-pretreated
animals, and ipsilateral GR mRNA levels are decreased in DG of all pretreatment groups after
injury. [A p ≤ 0.05 as compared to vehicle-pretreated animals within same surgical treatment
(effect of antagonist pretreatment).

B

p ≤ 0.05 as compared to sham-operated animals within

same pretreatment group (effect of CCI).]
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Discussion
CCI modulates HPA activation
The extent of HPA activation after TBI may influence neuronal survival, given evidence for
glucocorticoid exacerbation of several forms of neuronal injury (Sapolsky, 1985; Sapolsky and
Pulsinelli, 1985; Sapolsky, 1986a; Sapolsky et al., 1988; Goodman et al., 1996; McIntosh and
Sapolsky, 1996a). In the first experiment of this study, vehicle-pretreated animals demonstrated
equivalent plasma CORT levels 24 hours after sham operation and injury. The levels were
slightly higher than would be expected in unoperated rats but were not of a magnitude to saturate
GR binding at the 24-hour time point. Another study assessing ACTH and CORT levels in rats
following closed head injury reported similar results at 24 hours (Shohami et al., 1995).
Clinical studies have reported increased HPA activation in humans after head injury (King et
al., 1970; Pentelenyi and Kammerer, 1984). To determine if differential activation of the HPA
axis occurs during the first 24 hours after experimental CCI, a time course analysis of plasma
CORT and ACTH levels was performed in sham-operated versus injured rats. Blood sampling
over the 24-hour period following surgeries confirmed the differential activation of the HPA axis
in animals injured by CCI. Increased levels of ACTH and CORT were observed 1.5 hours
following injury, after which a prolonged, low level of CORT secretion was observed for at least
6 hours after injury.
Plasma ACTH and CORT levels six hours after surgery (time of day = 1800h) indicate a
disruption of normal circadian rhythms. Diurnal peaks in rodent ACTH and CORT secretion
normally occur near the onset of darkness (Ruhmann-Wennhold and Nelson, 1977; D'Agostino
et al., 1982; Kwak et al., 1992). ACTH levels in CCI-injured animals were indistinguishable
from baseline at 1800h, the time of lights-off, and plasma CORT concentrations, although
slightly elevated at 1800h, did not approach typical peak levels of 150-200 ng/ml (D'Agostino et
al., 1982; Kwak et al., 1992). Sham-operated animals also lacked ACTH and CORT rhythms,
exhibiting unchanged plasma hormone levels across the 24-hour period after surgery. Alteration
of circadian rhythms has been reported after surgery in rats (Levine et al., 1980) and in humans
(King et al., 1970; McIntosh et al., 1981; Pentelenyi and Kammerer, 1984), but the exact cause
for disruption in these subjects, whether by anesthesia or the trauma of craniotomy, remains to be
determined.
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Injured animals demonstrated an unusual peak in ACTH levels 18h after the onset of surgery
(time of day = 600h). While the significance of this increase is unclear, we speculate that
increased ACTH levels could result from decreased sensitivity to glucocorticoid-mediated
feedback. Decreased sensitivity to feedback normally occurs at the peak of the circadian rhythm
and after stress (Dallman, 1992) and could be precipitated by the stress of injury or alteration of
circadian rhythms.
ACR antagonists modulate plasma corticosterone levels
Blockade of MR-mediated feedback inhibition of the HPA axis may account for increased
plasma CORT levels observed in SPIRO/sham subjects (Table 5.1).

Our laboratory has

previously demonstrated increased basal CORT secretion with SPIRO administration (McCullers
and Herman, 2001) (Chapter Three), although some studies report no effect of SPIRO on
morning CORT levels (Chabert et al., 1984; Herman and Spencer, 1998; Yau et al., 1999).
Activation of MR is required to maintain CORT secretion at the low basal levels normally
observed in rats in the morning (Spencer et al., 1998). Furthermore, studies using the MR
antagonist RU28318 have consistently demonstrated that MR blockade increases adrenocortical
secretion (Ratka et al., 1989; van Haarst et al., 1997; Spencer et al., 1998). The mechanism
whereby CCI interacts with ACR antagonists to reduce CORT secretion is presently unknown.
The inhibitory influence of the hippocampus over HPA activation (Herman et al., 1989b;
Jacobson and Sapolsky, 1991) invites speculation that this structure may be involved. It is
possible that aberrant hippocampal activation subsequent to injury in combination with altered
ACR signaling might culminate in decreased HPA secretion, but support for this hypothesis will
require further study.
ACR antagonists regulate GR mRNA levels
SPIRO pretreatment did not alter MR mRNA levels in sham-operated animals (Figure 5.4).
Previously we have observed that SPIRO pretreatment (followed by i.p. saline injection)
increases MR mRNA levels by approximately 30-40% in CA1, CA3, and DG (McCullers and
Herman, 2001) (Chapter Three), and many preceding studies suggest that MR is subject to autoregulation (Herman et al., 1989a; Reul et al., 1989; Herman et al., 1993; Chao et al., 1998a). The
lack of MR mRNA upregulation observed in the SPIRO/sham-operated group may be
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attributable to significantly increased CORT secretion in these subjects (Table 5.1). MR mRNA
levels are negatively regulated by GR activation at high glucocorticoid levels (Herman et al.,
1989a; Herman et al., 1993). Thus, enhanced GR activation due to elevated CORT levels in
SPIRO/sham animals may attenuate the transcriptional effects of MR blockade.
Both MR antagonist SPIRO and GR antagonist RU486 increased GR mRNA levels in shamoperated animals (Figure 5.5). We have observed similar effects with administration of these
antagonists in other experiments (Herman and Spencer, 1998; McCullers and Herman, 2001)
(Chapter Three). These data, together with reports that GR agonist dexamethasone (Herman et
al., 1989a; Reul et al., 1989), MR agonist aldosterone, or low, MR binding doses of CORT
(Chao et al., 1998a) each reverse ADX-induced increases in GR mRNA provide compelling
evidence for regulation of hippocampal GR mRNA expression by both MR and GR.
CCI increases MR mRNA and decreases GR mRNA levels
Injury increased MR mRNA levels in CA1 and CA3 of MR and GR antagonist-pretreated
animals (Figure 5.4).

Increased MR mRNA levels in SPIRO-pretreated subjects may be

attributable to MR auto-regulation (Herman et al., 1989a; Reul et al., 1989; Herman et al., 1993;
Chao et al., 1998a); however, previous experiments in our laboratory have not indicated MR
mRNA upregulation with RU486 pretreatment (McCullers and Herman, 2001) (Chapter Three).
These results suggest that TBI influences ACR-mediated regulation of MR expression. It is
interesting to note that CORT levels are significantly lower in these groups as compared to
sham-operated animals (Table 5.1). These data raise the possibility that injury-induced CORT
secretion could influence MR mRNA levels through auto-regulatory processes.
Injury did not alter ipsilateral GR mRNA expression in CA1 and CA3 of vehicle-pretreated
animals (Figure 5.5). However, injury abolished autoregulatory effects of SPIRO and RU486,
sharply decreasing ipsilateral GR mRNA levels (as compared to sham) by approximately 5080% in antagonist-pretreated subjects. These results indicate that CCI suppresses or interferes
with GR autoregulatory processes in hippocampus. Our laboratory has reported similar effects
of excitotoxic insult with kainic acid (McCullers and Herman, 2001) (Chapter Three).
While it is clear that GR auto-regulation (Herman et al., 1989a; Reul et al., 1989) is disrupted
after injury, the extent to which GR mRNA levels may be further decreased due to cell loss is
presently ambiguous.

Nonetheless, decreases in GR signal in the ipsilateral DG of all
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pretreatment groups surpass the magnitude of cell loss experienced in this region (McCullers et
al., 2001b) (Chapter Four). We have observed similar GR mRNA decreases of approximately
40-55% in DG of vehicle, SPIRO, and RU486 pretreated animals 24h after excitotoxic insult
with kainic acid, at a dose which does not cause cell loss in DG (McCullers and Herman, 2001)
(Chapter Three).

Thus, multiple types of neuronal injury result in the significant down-

regulation of GR mRNA levels in DG.
The extent to which cell loss affects measurement of mRNA levels by in situ hybridization is
an important consideration that is presently undefined. In parallel subjects, CCI resulted in the
loss of approximately 40% of CA1 and CA3 pyramidal neurons and 10% of DG granule neurons
24 hours after injury, while no cell loss was observed in the contralateral hemisphere of injured
rats or in sham-operated subjects (McCullers et al., 2001b) (Chapter Four). If comparable loss is
assumed in this study, the lack of demonstrable GR mRNA decrement in injured, vehicle-treated
groups indicates that the in situ hybridization technique underestimates cell loss. The lack of
correlation between cell loss and mRNA level is also seen for MR, where levels are significantly
higher on the injured side. It is possible that GR mRNA is upregulated in CA1 and CA3 to
compensate for signal that would otherwise be decreased by cell loss; however, the increases in
MR mRNA argue against this explanation, as greater induction of MR mRNA would have to be
assumed. In conjunction with the differential effects of antagonist pretreatment, it is likely that
the observed levels of GR and MR are due to injury-related gene regulation rather than simple
cell loss. This notion is supported by the large and disproportionate loss of GR mRNA in DG,
the region showing least cell death following CCI.
Traumatic brain injury initiates a multitude of cellular and molecular cascades that influence
gene expression. Although it is difficult to isolate specific factors of the many that are likely to
influence neuronal GR expression, results from the current study and others (Lowy, 1990, 1992;
McCullers and Herman, 2001) (Chapter Three) suggest a role for glutamate in the regulation of
hippocampal GRs. Extracellular glutamate levels increase in hippocampus after CCI injury
(Faden et al., 1989) and kainic acid injection (Liu et al., 1997), and similar patterns of GR
mRNA downregulation are observed in hippocampus after both types of injury (McCullers and
Herman, 2001) (Chapter Three). Thus, excessive glutamate receptor activation may lead to
interference with antagonist-mediated autoregulatory effects and to the preferential
downregulation of GR mRNA in DG. Glutamate receptor activation and alterations in calcium
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signaling that accompany CCI (McIntosh et al., 1998c) could potentially regulate GR mRNA
levels via activation of transcription factors (Cabral et al., 2001), expression of neurotrophic
factors (Sarrieau et al., 1996), or altered neurotransmitter release (Seckl et al., 1990). The results
of this study also indicate that glucocorticoid secretion is increased immediately following CCI,
potentially exposing hippocampal neurons to endangering levels of hormone. Considering the
negative effects of excessive GR activation on injured hippocampal neurons, injury modulation
of HPA activation and ACR expression may influence hippocampal neuron viability after
traumatic injury.
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Chapter Six: Discussion
Adrenocorticosteriod receptor regulation of hippocampal neuron viability
The present thesis examines the respective roles of MR and GR on hippocampal neuron
vulnerability to injury. To isolate individual receptor effects on neuronal survival, MR and GR
antagonists were administered in subjects prior to excitotoxic challenge with KA or traumatic
injury by CCI. Cell counts performed twenty-four hours following insult tested the hypotheses
that MR blockade would increase and GR blockade would decrease hippocampal neuron
vulnerability to each form of injury. In addition, expression of bcl-2 and other viability-related
genes was examined following injury to determine if ACR antagonist effects on viability
correlate with regulation of the selected genes. Finally, MR and GR mRNAs were measured
after injury to test the hypothesis that glucocorticoid signaling is altered following injury via
regulation of hippocampal ACR expression.
Adrenocorticosteriod receptor regulation of hippocampal neuron survival
The results of these experiments support the hypotheses that MR protects and GR endangers
challenged hippocampal neurons. In support of the latter, GR antagonist RU486 prevented the
loss of CA1 neurons twenty-four hours following CCI injury (Chapter Four). The selective
protection of CA1 neurons may be due to regional differences in CCI injury or density of GR
expression (see Chapter Four).

The potential for RU486 neuroprotection against KA

excitotoxicity could not be evaluated due to the absence of measurable KA-induced injury in
vehicle and RU486-pretreated subjects (Chapter Three). The current work predicts that RU486
would protect hippocampal neurons subjected to a more severe KA lesion.
Pretreatment with SPIRO, an MR antagonist, increased vulnerability to KA excitotoxicity in
hippocampal field CA3 (Chapter Three).

While these results may suggest selective MR

protection of this region, the comparable distribution of MR in CA1 and CA3 suggests that
differential cell loss is more likely attributable to the selective vulnerability of CA3 neurons to
KA insult (Nadler et al., 1978). Whether MR blockade increases susceptibility to KA by
increasing injury severity or by lowering the neuronal threshold for cell death remains unclear.
MR blockade might exacerbate neuronal injury by disrupting cellular Ca2+ homeostasis.
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Adrenalectomy, which prevents endogenous CORT production and subsequent MR activation,
increases Ca2+ currents in CA1 neurons, while selective activation of MR results in very small
Ca2+ currents (Karst et al., 1994). Predominant MR activation may therefore reduce harmful
Ca2+ influx (Karst et al., 1994), whereas MR blockade may contribute to pathologic rises in
intracellular Ca2+. Alternatively, MR blockade may lower the neuronal “set point” for cell death
by modulating expression of pro- or anti- apoptotic factors, such as members of the bcl-2 family.
Following TBI, SPIRO did not exacerbate neuronal loss in CA1 and CA3. However, these
regions suffered substantial (35-40%) injury-induced neuronal loss in vehicle and SPIROpretreated subjects. Because CCI alone was sufficient to destroy vulnerable cells, compromising
effects of MR blockade may not have been evident at this level of injury.
Adrenocorticosteriod receptor regulation of viability-related gene expression
The current data indicate potential for ACR influence on neuronal survival via regulation of
the anti-apoptotic gene bcl-2. MR blockade with SPIRO decreased basal mRNA levels of the
survival-promoting gene bcl-2 in CA1 (Chapter Two), suggesting that SPIRO would increase
hippocampal vulnerability to insult in this region. However, subjects receiving KA injection
following SPIRO pretreatment exhibited no differential cell loss in CA1 (Chapter Three). In
addition, RU486 decreased bcl-2 levels in CA1 and DG of animals subjected to sham-CCI, yet
RU486 had a dramatic neuroprotective effect on CA1 neurons after CCI injury (Chapter Four).
Thus, ACR-induced decreases in bcl-2 mRNA expression observed in uninjured (saline-injected
or sham-operated) animals did not consistently predict increased vulnerability following injury.
Experiments in the present thesis do not provide support for bax, p53, BDNF, or NT-3
involvement in ACR modulation of hippocampal survival. Adrenocorticosteriod regulation of
hippocampal bax, BDNF, or NT-3 mRNA levels was not observed in any of the current
experiments (note that BDNF and NT-3 mRNA levels were not assessed in the CCI model). In
addition, ACR blockade had no significant effects on hippocampal p53 mRNA levels in CCIinjured hemispheres (Chapter Four). Kainic acid-induced increases in p53 mRNA levels were
attenuated by MR blockade in CA3, suggesting the potential for enhanced resistance to apoptosis
in this region, yet MR blockade increased CA3 vulnerability to KA excitotoxicity (Chapter
Three). Therefore, ACR-mediated effects on p53 expression do not appear to have significant
influence on hippocampal neuron survival.
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Adrenocorticosteriod receptor regulation of hippocampal neuron survival - potential mechanisms
Adrenocorticosteriod receptor modulation of calcium homeostasis
Altered Ca2+ homeostasis is proposed to be a key cellular mechanism underlying
glucocorticoid neurotoxicity.

Voltage-dependent Ca2+ currents are strongly regulated by

corticosteroids with U-shaped dose dependency; in CA1 of hippocampus, Ca2+ current amplitude
is large in the absence of corticosteroids, small under conditions of predominant MR activation,
and large with the additional occupation of GR at higher glucocorticoid levels (Kerr et al., 1992;
Karst et al., 1994; Werkman et al., 1997). Evidence suggests that neuronal Ca2+ influx is
enhanced by glucocorticoid modulation of L-type Ca2+ currents (Landfield and Eldridge, 1994;
Joels, 2001). In combination with depolarizing stimuli such as KA-induced seizures or excessive
levels of extracellular glutamate, GR-mediated increases in intracellular Ca2+ levels may enhance
neuronal vulnerability to Ca2+-related injury mechanisms (Landfield and Eldridge, 1991; Joels,
2001).
In addition to increasing Ca2+ influx, GR activation reduces Ca2+ extrusion in hippocampal
neurons (Elliott and Sapolsky, 1993; Joels, 2001). Consistent with these findings, high CORT
levels reduce expression of PMCA1 (Bhargava et al., 2000), a plasma membrane Ca2+ ATPase
responsible for translocating calcium from the cytosol to the extracellular space (Garcia and
Strehler, 1999). Overexpression of PMCA isoform 4 in pheochromocytoma 12 cells reduces
vulnerability to Ca2+-mediated cell death, suggesting that regulation of PMCA expression may
influence cellular survival of insults involving pathological increases in intracellular calcium
(Garcia et al., 2001).

In agreement with this hypothesis, KA administration decreases

hippocampal expression of PMCA isoforms 1 and 2 (Garcia et al., 1997b). Further reduction in
PMCA levels prompted by GR activation would be expected to intensify injury-induced rises in
intracellular Ca2+ levels and exacerbate neuronal degeneration.
Adrenocorticosteriod receptor blockade with MR or GR antagonists may influence
hippocampal neuronal viability by altering Ca2+ conductances or extrusion mechanisms.
Blocking MR activation with SPIRO should result in the predominant activation of GR.

It is

well established that voltage-dependent Ca2+ currents increase with GR activation at high CORT
levels (Kerr et al., 1992; Karst et al., 1994; Werkman et al., 1997). However, it is currently
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unclear whether exclusive GR activation is sufficient to induce large Ca2+ currents in
hippocampal neurons. Electrophysiological studies in hippocampal slices have reported mixed
results; one study indicates that GR agonist RU28362 increases Ca2+ currents in CA1 neurons
(Kerr et al., 1992) while another indicates that it does not (Karst et al., 1994). If exclusive GR
activation is indeed sufficient to increase Ca2+ currents, then SPIRO blockade of MR may
endanger hippocampal neurons by enhancing Ca2+ influx, particularly under conditions of GRsaturating CORT levels. In terms of the current experiments, this scenario is consistent with the
increased vulnerability of CA3 neurons to KA toxicity following SPIRO pretreatment (Chapter
Three).
Glucocorticoid receptor blockade with RU486 should result in the predominant activation of
MR. Exclusive MR occupation yields relatively small Ca2+ currents (Karst et al., 1994) and may
thus protect hippocampal neurons from exposure to excessive Ca2+ influx. In addition, GR
blockade should prevent GR-mediated repression of PMCA isoforms, improving Ca2+ extrusion
mechanisms.

These beneficial effects of GR blockade on neuronal Ca2+ homeostasis are

consistent with the neuroprotective effects of RU486 on CA1 neurons following TBI (Chapter
Four).
Adrenocorticosteriod receptor suppression of inflammation
Glucocorticoids inhibit synthesis, release, and/or function of many factors involved in the
inflammatory response, including: cytokines, such as interleukin (IL)-1β, IL-2, IL-3, IL-5, IL-6,
IL-12, and tumor necrosis factor alpha (TNF-α); chemokines such as IL-8; and inflammatory
mediators and enzymes such as histamine, bradykinin, and nitric oxide (Cato and Wade, 1996;
Steer et al., 1997; Sapolsky et al., 2000).

Glucocorticoids also repress expression of

cyclooxygenase 2 (COX-2) (Cato and Wade, 1996; Sapolsky et al., 2000), an enzyme that
catalyzes prostaglandin formation (Rivest, 1999). Further, glucocorticoids inhibit expression of
adhesion molecules, alter lymphocyte trafficking, and reduce activation and proliferation of B
and T cells (Cato and Wade, 1996; Sapolsky et al., 2000). Glucocorticoid inhibition of KAinduced AP-1 (Unlap and Jope, 1995a) and NF-κB (Unlap and Jope, 1995b) DNA binding has
been demonstrated, suggesting that the potent anti-inflammatory and immunomodulatory action
of glucocorticoids may be mediated in part through repression of AP-1 and NF-κB activity (De
Bosscher et al., 2000).
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Inflammation has been proposed to influence neuronal survival following several forms of
insult including KA-mediated excitotoxicity and traumatic brain injury. Kainic acid increases
glial expression of several cytokines in hippocampus and cortex including IL-1β (Minami et al.,
1991; Yabuuchi et al., 1993; Eriksson et al., 2000). Administration of IL-1ra, an endogenous
antagonist of IL-1, protects neurons against KA-induced degeneration in CA1 and CA3,
suggesting a deleterious role for IL-1β in excitotoxic neuronal death (Panegyres and Hughes,
1998). Hippocampal and cortical mRNA levels of IL-1β also increase following experimental
TBI (Fan et al., 1995). Administration of IL-1 receptor antagonist IL-1ra has been shown to
reduce cortical lesion volume (Toulmond and Rothwell, 1995), attenuate hippocampal neuron
loss, and improve cognitive function following lateral fluid percussion (Sanderson et al., 1999),
providing further evidence that IL-1β may contribute to injury-mediated neurodegeneration. As
glucocorticoids decrease IL-1 production (McEwen et al., 1997), ACR regulation of this
cytokine should enhance neuronal survival after injury and would not appear to explain the
endangering effects of GR.
Other studies raise the possibility that mediators of inflammation may play a neuroprotective
role after neuronal injury.

Mice lacking IL-6 demonstrate increased susceptibility to KA-

induced damage in hippocampus, suggesting that IL-6 can improve survival after excitotoxic
injury (Penkowa et al., 2001). In addition, selective inhibitors of COX-2 exacerbate KA-induced
neuronal degeneration in hippocampus (Baik et al., 1999) and worsen motor performance
following TBI (Dash et al., 2000), indicating a protective role for COX-2. Glucocorticoids
decrease IL-6 production (McEwen et al., 1997) and inhibit COX-2 expression (Masferrer et al.,
1992), raising the possibility that the anti-inflammatory effects of glucocorticoids may contribute
to neuronal vulnerability to injury.
Glucocorticoids may also increase neuronal vulnerability to injury via suppression of TNF-α,
a pro-inflammatory cytokine that is rapidly induced after several types of brain injury including
KA excitotoxicity (Minami et al., 1991; de Bock et al., 1996) and TBI (Taupin et al., 1993; Fan
et al., 1996; Knoblach et al., 1999). The role for TNF-α in mediating neuronal survival is
controversial; several studies indicate that inhibition of TNF-α reduces neurological deficits and
hippocampal damage following TBI (Shohami et al., 1996; Shohami et al., 1997; Knoblach et al.,
1999). However, increasing evidence suggests that TNFα may have neuroprotective effects
under certain circumstances following central nervous system insult. Pretreatment with TNF-α
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protects cultured hippocampal neurons against oxidative insults (Barger et al., 1995; Mattson et
al., 1997), excitatory amino acid toxicity (Cheng et al., 1994), and injury induced by glucose
deprivation (Cheng et al., 1994). In addition, TNF-deficient mice exhibit long-lasting motor
deficits following CCI brain injury as compared to wild-type (despite increased memory and
motor deficits within the acute posttraumatic period), suggesting that TNF may facilitate longterm recovery after brain injury (Scherbel et al., 1999). Further, mice lacking TNF receptors are
more susceptible to neuronal loss induced by focal cerebral ischemia and KA administration
(Bruce et al., 1996). TNF-α appears to protect neurons by stabilizing cellular Ca2+ homeostasis
and stimulating antioxidant pathways via activation of NF-κB (Cheng et al., 1994; Barger et al.,
1995; Bruce et al., 1996; Mattson et al., 1997; Furukawa and Mattson, 1998). Glucocorticoids
may counter these potentially neuroprotective effects through suppression of TNF-α release from
monocytes and macrophages (Joyce et al., 1997; Steer et al., 1997) and inhibition of NF-κB
activation (De Bosscher et al., 2000).
Glucocorticoids have been proposed to protect the organism by limiting inflammatory
responses that, left unchecked, might threaten cellular homeostasis (Munck et al., 1984). In this
view, it is possible that glucocorticoids prevent excessive activation of mediators of
inflammation that would otherwise contribute to neuronal degeneration after injury. However, it
is also possible that glucocorticoid suppression of the beneficial effects of inflammation, such as
Ca2+ regulation and the expression of antioxidants (Wong and Goeddel, 1988; Cheng et al.,
1994), may contribute to neuronal degeneration. Administration of RU486 would be expected to
attenuate the anti-inflammatory effects of GR activation, as RU486 has been shown to reverse
GR suppression of TNFα release from monocytes (Steer et al., 1997). Thus, RU486 repression
of anti-inflammatory glucocorticoid effects may contribute to the improved survival of
hippocampal neurons after injury.
Adrenocorticosteriod receptor regulation of hippocampal neurotrophic factor expression
Despite negative findings reported in the current work, the possibility for glucocorticoid
modulation of neuronal viability via regulation of neurotrophic factors can not be dismissed.
Due to the twenty-six hour time period between antagonist injection and decapitation, ACR
antagonist effects on BDNF or NT-3 mRNA levels may not have been detected. Glucocorticoid
regulation of BDNF expression is rapid and transient; hippocampal BDNF mRNAs are reduced
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within one hour after the onset of stress, recover substantially by four hours, and return towards
baseline levels within twenty-four hours (Smith et al., 1995b). Similarly, hippocampal nerve
growth factor mRNA levels peak approximately three hours after CORT injection, fall below
baseline levels by six hours, and return close to control levels by 24 hours (Lindholm et al.,
1994), emphasizing the transitory nature of growth factor induction. In addition, neurotrophin
levels were not assessed in sham and CCI-injured animals in the current work, and ACR effects
on numerous other trophic factors remain to be investigated.
Several previous studies validate the possibility that ACR regulation of neurotrophic factors
may influence hippocampal vulnerability to injury. Although reports are not entirely consistent,
there is general agreement that in specific hippocampal subfields, CORT and stress decrease
hippocampal BDNF mRNA levels, while adrenalectomy increases BDNF mRNAs and decreases
NT-3 mRNAs in hippocampus (Chao and McEwen, 1994; Smith et al., 1995a, b; Schaaf et al.,
1997; Chao et al., 1998b). Futher, CORT and dexamethasone have been shown to increase nerve
growth factor mRNA levels (Lindholm et al., 1994; Scully and Otten, 1995). There is also
evidence to indicate that glucocorticoids regulate neurotrophic factor expression following
injury. Adrenalectomy attenuates BDNF mRNA induction and nearly abrogates NGF mRNA
induction by KA, and GR agonist dexamethasone enhances NGF mRNA induction by KA
(Barbany and Persson, 1993). In cultured hippocampal neurons, KA-induced increases in BDNF
mRNAs are negated by dexamethasone (Cosi et al., 1993). Furthermore, serum deprivationinduced death of cultured hippocampal neurons is accelerated by CORT and associated with
decreases in BDNF mRNA levels and protein (Nitta et al., 1999). Addition of BDNF to serumdeprived cultures attenuates negative CORT effects, supporting the hypothesis that reduced
synthesis of BDNF contributes to CORT-mediated endangerment of hippocampal neurons (Nitta
et al., 1999). A recent study has also demonstrated that glucocorticoids influence neurotrophic
factor expression following TBI.

Adrenalectomy enhances fluid percussion injury-induced

increases in BDNF mRNA levels, an effect that is reversed with administration of CORT
(Grundy et al., 2000).

Adrenalectomy also prevents and CORT replacement permits the

induction of NGF mRNA levels following fluid-percussion injury, indicating the essential role of
CORT in the NGF response (Grundy et al., 2001).
Despite evidence for glucocorticoid regulation of neurotrophic factor expression following
injury, the potential impact of this regulation on hippocampal neuronal viability is presently
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unclear. High glucocorticoid levels decrease BDNF mRNAs and increase pyramidal neuron
vulnerability to injury (Sapolsky, 1994; Smith et al., 1995b), suggesting reduced BDNF
expression as a potential mechanism for glucocorticoid toxicity. Reports demonstrating an
association between decreased BDNF mRNA levels and increased neuronal degeneration support
this hypothesis (Hicks et al., 1999; Nitta et al., 1999). In contrast, the attenuation of KA-induced
increases in BDNF expression by adrenalectomy is not consistent with a protective role for
glucocorticoid removal (Barbany and Persson, 1993). The neuroprotective value of BDNF is
also uncertain, as exogenous administration of BDNF has been shown to exacerbate CA3
neuronal loss following KA administration (Rudge et al., 1998). Furthermore, glucocorticoids
potentiate NGF expression and maintain NT-3 mRNA levels, in seeming disagreement with the
profile for neuronal endangerment by glucocorticoids. The literature suggests that blockade of
GR with RU486 should enhance KA- and TBI-mediated induction of BDNF expression, while
decreasing injury-induced NGF expression. However, the potential effects MR blockade on
injury-induced neurotrophin expression are less clear because it has not been established whether
GR activation alone is sufficient for neurotrophin regulation. Clarification of these issues will
require further study.
Summary
The present thesis provides evidence supporting the hypotheses that MR protects and GR
endangers hippocampal neurons following specific types of neuronal injury.

The current

experiments did not support the hypotheses that ACR effects on neuronal survival involve the
regulation of bcl-2, bax, or p53 expression. Rather, the widespread effects of glucocorticoids on
several other systems crucial to neuronal survival suggest that glucocorticoids influence
hippocampal neuron viability via more global mechanisms. Glucocorticoids exert direct effects
on cellular metabolism, Ca2+ homeostasis, inflammatory processes, and neurotrophic factor
expression; in addition, these targets are largely interrelated and capable of altering one another
(Figure 6). For instance, glucocorticoid effects on neurotrophin expression, cytokine production,
and cellular metabolism can influence intracellular Ca2+ levels (Sapolsky, 1990; Mattson and
Scheff, 1994; Tymianski and Tator, 1996; Jiang and Guroff, 1997). In turn, Ca2+ influx can
modulate neurotrophin expression (Finkbeiner, 2000), regulate cytokine production (Hotchkiss
and Karl, 1996), and disrupt mitochondrial production of ATP (Green and Reed, 1998). It
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becomes clear that glucocorticoid effects on hippocampal neuron viability are not likely carried
out via isolated signaling pathways, but rather they result from the integration of many factors
associated with the injury response.

Figure 6. Potential mechanisms for glucocorticoid modulation of hippocampal neuron survival
after injury.

Excessive activation of the glucocorticoid receptor may impair antioxidant

defenses, suppress neuroprotective inflammatory responses, decrease neuronal energy stores,
increase voltage-dependent Ca2+ currents, and compromise ATP-dependent processes
responsible for maintaining membrane potential. All of these factors may culminate to increase
oxidative stress and intracellular Ca2+ levels, potentially leading to neuronal death.
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Injury regulation of adrenocorticosteroid receptor mRNA levels
Experiments in the current thesis reveal that hippocampal ACR mRNA levels are
dramatically regulated by excitotoxic and traumatic injury (Chapters 6 and 8). Kainic acid
decreased MR mRNA levels by approximately 40% in CA1 and CA3 and decreased GR mRNA
levels by approximately 40% in DG (Chapter Three). Traumatic injury did not influence MR
mRNA levels but had powerful effects on GR levels; CCI decreased GR levels by approximately
30% in DG of the injured hemisphere and increased GR levels by approximately 20% in CA1
and DG of the contralateral hemisphere (Chapter Five). These data support the hypothesis that
glucocorticoid signaling is altered through regulation of ACR expression following injury.
Injury regulation of adrenocorticosteroid receptor mRNA levels – potential mechanisms
As discussed in Chapters Three and Five, altered ACR expression following KA
administration and CCI is not attributable to CORT-mediated auto-regulatory mechanisms. Still,
the downregulation of dentate gyrus GR mRNA levels by both types of injury suggests the
possibility of a common regulatory mechanism.

Potential candidates for this role include

glutamate receptor activation and Ca2+ signaling, as both KA-induced seizures and TBI lead to
the accumulation of extracellular glutamate and increased intracellular Ca2+ levels (Ben-Ari,
1985; Faden et al., 1989; Sun et al., 1992; McIntosh et al., 1998c).
Glutamate regulation of adrenocorticosteriod receptor mRNA levels
Receptor expression patterns provide no evidence for differential action of ionotropic
glutamate receptors in DG, as NMDA and AMPA glutamate receptor subtypes are preferentially
expressed in CA1, and KA receptors are mainly located in stratum lucidum of CA3 (Foster et al.,
1981; Represa et al., 1987). However, metabotropic glutamate receptor subtype 1 (mGluR1) is
strongly expressed in granule neuron cell bodies and the molecular layer of dentate gyrus
(Shigemoto et al., 1997), and mGluR1 expression is increased in dentate gyrus following
systemic KA injection (Blumcke et al., 2000). The literature provides support for mGluR
activation as a viable candidate mechanism for regulation of GR expression after injury. Group
1 mGluRs, which include mGluR1 and mGluR5, stimulate formation of cyclic adenosine
monophosphate (cAMP) (Aramori and Nakanishi, 1992), which has been shown to decrease GR
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expression in multiple cell lines. The cAMP analog 8-bromo-cAMP decreases GR binding in
mouse AtT20 anterior pituitary corticotrope tumor cells, and forskolin, a drug that stimulates
adenylate cyclase, decreases GR binding and mRNA levels (Sheppard et al., 1991). In addition,
treatment with dibutyryl cAMP, another cAMP analog, decreases GR protein levels in rat C6
glioma cells, B104 neuroblastoma cells, and in rat primary hippocampal and cortical cultures
(Sipe, 2000). Thus, activation of mGluR1 represents a possible mechanism whereby injury may
decrease GR expression in DG via cAMP-dependent pathways.
Calcium regulation of adrenocorticosteriod receptor mRNA levels
Intracellular Ca2+-dependent signaling may also mediate injury-induced changes in ACR
expression. Calcium influx (Young, 1992; Fineman et al., 1993; Tymianski and Tator, 1996) has
been hypothesized to regulate changes in gene expression induced by both kainate (Pennypacker
and Hong, 1995) and TBI (McIntosh et al., 1997; Morrison et al., 2000). Furthermore, Ca2+
regulation of GR expression has been demonstrated in vitro in AtT-20 cells (Sheppard, 1994).
However, the lack of Ca2+ accumulation in DG following KA injection (in contrast to significant
Ca2+ accumulation in CA3) (Friedman, 1997) and the high density of Ca2+-binding proteins in
DG (Sloviter, 1989) indicate that GR downregulation does not simply correspond to overall Ca2+
load. Rather, Ca2+-mediated regulation of GR expression might occur via distinct Ca2+ signaling
pathways linked to specific routes of Ca2+ influx, such as L-type voltage-dependent Ca2+
channels (Bading et al., 1993). In support of this hypothesis, treatment with BAY K8644, which
selectively promotes Ca2+ influx through L-type Ca2+ channels, decreases GR binding in AtT-20
cells (Sheppard, 1994).
Injury regulation of adrenocorticosteroid receptor mRNA levels – potential influence on
hippocampal neuron viability
Potential effects of GR downregulation on hippocampal circuitry
Ample evidence supports the hypothesis that GR compromises survival of CA1 and CA3
pyramidal neurons after injury, yet GR activation does not appear to compromise DG granule
neuron survival after administration of KA or TBI. Nonetheless, alterations in dentate neuron
excitability may influence downstream synaptic transmission and the survival of pyramidal
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neurons, as DG is the major recipient of perforant path projections from the entorhinal cortex and
delivers the majority of excitatory input into CA3 (Amaral and Witter, 1989) (see Figure 1.5).
Electrophysiological studies demonstrating GR attenuation of CA1 neuron excitability (Kerr et
al., 1989) raise the possibility that decreased GR expression in DG may enhance KA and TBIinduced granule neuron hyperexcitability (Lowenstein et al., 1992; Sloviter, 1992; Santhakumar
et al., 2000), potentially contributing to excitotoxic stress in CA3 and CA1. However, a recent
report demonstrates that in contrast to CA1, GR activation does not suppress synaptically evoked
field potentials in dentate gyrus (Stienstra and Joels, 2000), indicating that decreased GR
expression may not influence excitability in this region. In addition, GR blockade, which should
have a maximal effect if any on glucocorticoid-modulated synaptic transmission, does not
compromise CA3 or CA1 survival after TBI (Chapter Four). It therefore does not appear likely
that altered GR expression influences pyramidal neuron survival via modulation of DG synaptic
transmission.
Alternatively, downregulation of GR expression may facilitate rearrangement of DG circuitry
after excitotoxic and traumatic brain injury.

This hypothesis is supported by studies

investigating reactive synaptogenesis in response to entorhinal cortex lesion in the rat.
Glucocorticoids inhibit axon sprouting (Scheff and Cotman, 1982) and influence synaptic
replacement (Scheff et al., 1986) in DG following delivery of entorhinal cortex lesion. In
addition, an approximately 33% bilateral decrease in GR mRNA levels has been observed in DG
one day following unilateral entorhinal cortex lesion (O'Donnell et al., 1993). The authors of
this study proposed that decreased GR expression might serve to attenuate glucocorticoid
inhibition of lesion-induced synaptogenesis (O'Donnell et al., 1993). Strikingly, the patterns of
GR downregulation following entorhinal cortex lesion, kainic acid insult, and TBI are very
similar (Chapters Three and Five), raising speculation that decreased expression of GR in dentate
gyrus may have a permissive effect on restructuring of DG circuitry following multiple types of
injury. Kainic acid is known to induce mossy fiber sprouting (Davenport et al., 1990), but the
extent of DG remodeling induced by TBI remains to be investigated.
Potential effects of GR downregulation on neurogenesis
In addition to facilitating rearrangement of residual DG circuitry, downregulation of GR
expression may influence DG neurogenesis after injury. Neurogenesis of DG granule cells
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continues well into adulthood in the rat and is inhibited by corticosterone in a concentrationdependent manner (Cameron and Gould, 1994). Kainic acid (Gray and Sundstrom, 1998) and
TBI (Dash et al., 2001) have both been shown to enhance DG neurogenesis. GR downregulation
in dentate gyrus after KA and traumatic brain injury may therefore facilitate injury-induced
neurogenesis and the subsequent restoration of functional DG circuitry.
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Summary
The present thesis supports the hypotheses that MR activation enhances and GR activation
endangers neuronal survival in specific hippocampal subregions following excitotoxic or
traumatic brain injury. Experiments in the current work demonstrate a neuroprotective effect of
GR blockade after experimental TBI in vivo, as pretreatment with RU486 prevented CCIinduced neuronal loss in hippocampal subregion CA1 (Chapter Four). The present data also
provide evidence that MR protects hippocampal neurons following excitotoxic injury, as MR
blockade with SPIRO increased CA3 cell loss following systemic KA injection (Chapter Three).
In addition, this work demonstrates KA and TBI-induced downregulation of GR mRNA levels in
dentate gyrus, which may facilitate the recovery of functional DG circuitry after injury (Chapters
Three and Five). Adrenocorticosteroid receptors clearly influence hippocampal neuron survival
after injury, and future study of ACR regulation under challenging conditions could contribute to
the improved treatment of seizure, stroke, traumatic injury, and neurodegenerative diseases.
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Appendix
List of Abbreviations
mineralocorticoid receptor (MR), glucocorticoid receptor (GR), adrenocorticosteroid receptor
(ACR), mifepristone (RU486), hypothalamic-pituitary-adrenal (HPA), corticotropin-releasing
hormone (CRH), adrenocorticotropin-releasing hormone (ACTH), paraventricular nucleus of the
hypothalamus (PVN), heat shock protein (HSP), glucocorticoid response element (GRE),
activator protein-1 (AP-1), cyclic AMP response element binding protein (CREB), nuclear
factor-κB (NF-κB), negative glucocorticoid response element (nGRE), calcium (Ca2+),
corticosterone (CORT), plasma membrane calcium pump isoform 1 (PMCA1), brain-derived
neurotrophic factor (BDNF), neurotrophin-3 (NT-3), excitatory postsynaptic potential (EPSP),
entorhinal cortex (EC), subicular complex (S), nerve growth factor (NGF), apoptosis-inducing
factor (AIF), apoptotic protease activating factor-1 (Apaf-1), inhibitor of CAD (ICAD), caspaseactivated deoxyribonuclease (CAD), traumatic brain injury (TBI), controlled cortical impact
(CCI), anti-apoptotic B-cell leukemia/lymphoma-2 gene (bcl-2), messenger RNA (mRNA),
interleukin (IL), tumor necrosis factor alpha (TNF-α), cyclooxygenase 2 (COX-2), metabotropic
glutamate receptor subtype 1 (mGluR1), cyclic adenosine monophosphate (cAMP)
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